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ABSTRACT

Provided herein are novel acyltransferases and methods of
using Such novel acyltransferases in making medium-chain
fatty acids.
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NOVELACYLTRANSERASES AND
METHODS OF USING
CROSS REFERENCE TO RELATED
APPLICATIONS

0001. This application claims the benefit of priority under
35 U.S.C. S 119(e) to U.S. Application No. 61/917,586 filed
Dec. 18, 2013. The entirety of the prior application is incor
porated by reference.
FEDERALLY SPONSORED RESEARCHOR
DEVELOPMENT

0002 This invention was made with government support
under DE-SC0001295, 2009-05988, and IOS 0701919

awarded by the U.S. Department of Energy, the U.S. Depart
ment of Agriculture, and the National Science Foundation,
respectively. The government has certain rights in the inven
tion.

sequence identity to SEQ ID NO:9. In some embodiments,
the nucleic acid sequence encoding the at least one acyltrans
ferase is selected from the group consisting of a nucleic acid
sequence having at least 95% sequence identity to SEQ ID
NO:1, a nucleic acid sequence having at least 95% sequence
identity to SEQID NO:3, a nucleic acid sequence having at
least 95% sequence identity to SEQID NO:7, and a nucleic
acid sequence having at least 95% sequence identity to SEQ
ID NO:9.

0008. In some embodiments, the organism further com
prises a nucleic acid sequence encoding a medium-chain fatty
acid (MCFA)-specific thioesterase FatB. In some embodi
ments, the nucleic acid sequence encoding the MCFA-spe
cific thioesterase FatB is selected from the group consisting of
a nucleic acid sequence having at least 95% sequence identity
to SEQ ID NO:11, a nucleic acid sequence having at least
95% sequence identity to SEQID NO:13, and a nucleic acid
sequence having at least 95% sequence identity to SEQ ID
NO:15.

TECHNICAL FIELD

0003. This disclosure generally relates to transgenic
plants.
BACKGROUND

0004 Plants in the genus, Cuphea (Lythracea), accumu
late high levels of medium chain fatty acids (MCFAs) in their
seeds. MCFAs are useful in the chemical industry in the
production of detergents, lubricants and biofuels. Camelina
sativa is a member of the Brassicaceae family, and has been
found to be a sustainable source of oil for petroleum products.
A high proportion of polyunsaturated fatty acids in Camelina
oil, however, has limited its usefulness in the biofuel industry.
Therefore, methods of engineering the oil properties in Cam
elina or other oil-producing organisms are desirable.
SUMMARY

0005. In one aspect, a method of producing triacylglycer
ols (TAGs) comprising medium-chain fatty acids (MCFAs) in
an organism is provided. Such a method typically includes
introducing a transgene into the organism, wherein the trans
gene comprises at least one nucleic acid sequence encoding
an acyltransferase, wherein the at least one acyltransferase
exhibits a substrate specificity for saturated fatty acids,
thereby producing TAGs comprising MCFAS in the organism.
0006. In some embodiments, at least 20% (at least 40%, at
least 50%, etc., etc.) of the TAGs comprising MCFAs have a
C8:0 or a C10:0 at sn-2 position. In some embodiments, the
saturated fatty acids are selected from the group consisting of
C8:0 and C10:0.

0007. In some embodiments, the at least one acyltrans
ferase is a lysophosphatidic acid acyltransferase (LPAT) or a
diacylglycerol acyltransferase (DGAT). In some embodi
ments, the at least one acyltransferase is a lysophosphatidic
acid acyltransferase (LPAT) and a diacylglycerol acyltrans
ferase (DGAT). In some embodiments, the nucleic acid
sequence encoding the LPAT is selected from the group con
sisting of a sequence having at least 95% sequence identity to
SEQID NO:1 and a sequence having at least 95% sequence
identity to SEQID NO:3. In some embodiments, the nucleic
acid sequence encoding the DGAT is selected from the group
consisting of a sequence having at least 95% sequence iden
tity to SEQ ID NO:7 and a sequence having at least 95%

0009. In some embodiments, the organism is selected
from the group consisting of a plant and a microbe. In some
embodiments, the plant is Camelina sativa.
0010. In some embodiments, the transgene comprises a
promoter. In some embodiments, the promoter is a seed
specific promoter. In some embodiments, the at least one
nucleic acid sequence encoding an acyltransferase is oper
ably linked to a seed-specific promoter. In some embodi
ments, the medium-chain fatty acids are produced in the seed.
0011. In some embodiments, the introducing step is per
formed using Agrobacterium transformation, particle bom
bardment, or electroporation of protoplasts.
0012. In another aspect, a method of producing triacylg
lycerols (TAGs) comprising medium-chain fatty acids (MC
FAs) is provided. Such a method typically includes providing
an organism comprising a transgene, wherein the transgene
comprises at least one nucleic acid sequence encoding an
acyltransferase, wherein the at least one acyltransferase
exhibits a Substrate specificity for Saturated fatty acids; grow
ing the organism under appropriate conditions; and obtaining
TAGs comprising MCGAS from the organism. In some
embodiments, the TAGs are used in biofuel, jet fuel, deter
gents, and chemical feedstocks.
0013. In still another aspect, a method of increasing the
amount of triacylglycerols (TAGs) comprising medium
chain fatty acids (MCFAs) in the seed oil of a plant is pro
vided. Such a method typically includes providing a plant
comprising a nucleic acid encoding a FatB polypeptide; intro
ducing a heterologous nucleic acid molecule into the plant
comprising at least one nucleic acid sequence encoding an
acyltransferase, wherein the at least one acyltransferase
exhibits a substrate specificity for saturated fatty acids,
thereby increasing the amount of TAGs comprising MCFAs
in the seed oil of the plant without significantly changing the
total oil content in the seed.

0014. Unless otherwise defined, all technical and scien
tific terms used herein have the same meaning as commonly
understood by one of ordinary skill in the art to which the
methods and compositions of matter belong. Although meth
ods and materials similar or equivalent to those described
herein can be used in the practice or testing of the methods
and compositions of matter, Suitable methods and materials
are described below. In addition, the materials, methods, and

examples are illustrative only and not intended to be limiting.
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All publications, patent applications, patents, and other ref
erences mentioned herein are incorporated by reference in
their entirety.
DESCRIPTION OF DRAWINGS
Part A

0015 FIG. 1 shows the phylogenic relationship in
deduced amino acid sequences of LPATs. Amino acid
sequences of 6 LPATs from Cuphea pulcherrima (black tri
angle) and 1 LPAT from Cuphea viscosissima (gray triangle)
were aligned with putative orthologs of higher plants, which
were obtained from the protein database of National Center
for Biotechnology Information (NCBI). The phylogenic tree
was built with the MEGA6 software, using the minimum
evolution method with 1000 number of bootstrap replication.
0016 FIG. 2 are the results of RT-PCR analysis showing
spatial expression of Cuphea LPAT genes in diverse tissues.
The Cuphea eIF4 and actin were used as internal controls.
0017 FIG. 3 are photographs showing the subcellular
localization of Cuphea LPATs. Single plane image of tobacco
epidermal cells was obtained from confocal laser scanning
microscopy. Left panels are YFP signals of Cuphea LPATs,
middle panels are ER markers (A, C and D) and auto fluores
cence of chloroplasts (B), and right panels are merged
images. Bars=10 um. (A) CpulPATB; (B) CpulPAT1: (C)
CpuLPAT2a: (D) CvLPAT2.
0018 FIG. 4 is data showing the complementation test of
Cuphea LPATs in mutated E. coli. The new Cuphea LPATs
were transformed into the E. coli JC201 strain, a mutant strain

that will not grow at non-permissive temperatures without a
functional LPAT.

0019 FIG. 5A is a graph showing the fatty acid composi
tion of lipids (Mol% of TAG).
0020 FIG. 5B is a graph showing the fatty acid composi
tion of the sn-2 position of seed oil TAG.
0021 FIG. 5C is a graph showing the total amount of
FAME (ug)/weight (mg).
0022 FIG.5D is a graph showing the fatty acid composi
tion of lipids (Mol% of TAG).
0023 FIG. 5E is a graph showing the fatty acid composi
tion of the sn-2 position of seed oil TAG.
0024 FIG. 5F is a graph showing the total amount of
FAME (ug)/weight (mg).
0025 FIG. 6 shows data demonstrating C14:0-containing
TAG species detected by Neutral Loss ESI-MS/MS. Electro
spray mass spectroscopy of TAG isolated from wild type (A)
and 14:0 specific CpFatB2 (B) with CpuLPATB (C), CnL
PATB (D), and CvLPAT2 (E). CN indicates the carbon num

ber of TAG.

0026 FIG. 7 provides the amino acid alignment of Cpull
PATB homologs and information regarding the predicted
transmembrane segments. (A) Amino acid alignment using
the CLUSTAWL algorithm was generated using LPLAT-AG
PAT-like domains of LPATB and LPAT1 homologs. Gray
dotted boxes indicate acyltransferase motifs. Circles and
black triangles are catalytic amino acids and binding site in
acyltransferase motifs, respectively. (B) Predicted transmem
brane region of CpulPATB by different programs; SOSUI,
PSORTII, HMMTOP, and TMHMM server 2.0. The numbers

indicate the amino acid residue of CpulPATB. (C) A sche
matic showing topological transmembrane and acyltransferse
motifs of CpuLPATB.

0027 FIG. 8 provides the amino acid alignment of CVL
PAT2 homologs and information regarding the predicted
transmembrane segments. (A) Amino acid alignment using
the CLUSTAWL algorithm was generated using LPLAT-AG
PAT-like domains of LPAT2 and LPAT3 homologs. Gray
dotted boxes indicate acyltransferase motifs. Circles and
black triangles are catalytic amino acids and binding site in
acyltransferase motifs, respectively. (B) Predicted transmem
brane region of CvLPAT2 by different programs; SOSUI,
PSORTII, HMMTOP, and TMHMM server 2.0. The numbers

are indicated the amino acid residue of CpulPATB. (C) A
schematic showing the topological transmembrane and acyl
transferase motifs of CvLPAT2.

0028 FIG. 9 are graphs showing LPAT activity expressed
in Agro-infiltrated tobacco leaf.
(0029 FIG. 10 is data showing the C10:0-containing TAG
species detected by Neutral Loss ESI-MS/MS. Electrospray
mass spectroscopy of TAG isolated from wild type (A) and
14:0 specific ChFatB2 (B) with CnLPATB (C) and CvLPAT2
(D). CN indicates the carbon number of TAG. *: contains
10/10/18:1, S: contains 10/10/20:1.
Part B

0030 FIG. 11 is an unrooted phylogram of C. pulcherrima
DGAT1 (Cp)GAT1) and other hypothetical and functionally
characterized DGATs. The alignment was generated by the
CLUSTALW program and the unrooted phylogram was con
structed by the neighbor-joining method in MEGA4 software
(Tamura et al., 2007, Mol. Biol. Evol., 24:1596-9).
0031 FIG. 12 is an alignment of deduced amino acid
sequence of Cpl DGAT1 with some of its orthologs.
0032 FIG. 13 is data showing CplDGAT1, CpDGAT2 A,
CpGAT2 B and Cpl DGAT2 C expression analysis in C.
pulcherrima tissues by SQRT-PCR of cDNA from total RNA.
PCR products were obtained with gene specific primers for
CpDGAT1, CplDGAT2 A, CpDGAT2 B or CpDGAT2 C.
0033 FIG. 14 is a graph showing the short and medium
chain fatty acid profile of CvFATb1+CpDGAT1 (T2) lines.
0034 FIG. 15 is a graph showing the short and medium
chain fatty acid profile in CvFatB1+CvLPAT2+CpDGAT1
(T2) lines.
0035 FIG. 16 is a graph showing the fatty acid profile of
TAG from transgenic Camelina plants
0036 FIG. 17 is a graph showing the fatty acid profile of
MAG species separated following the digestion of TAG from
mature seeds of wild type and transgenic Camelina CvFatB1,
CvFatB1+CvLPAT2, CvFatB1+CplDGAT1, CvFatB1+CvL
PAT2+Cpl DGAT1 lines and C. pulcherrima and C. viscosis
SiC.

0037 FIG. 18A is a graph showing the fatty acid profile in
developing seeds from wild type and transgenic Camelina
lines expressing CvFatB1, CvFatB1+CpGAT1, or
CvFatB1+CvLPAT2+CpDGAT1 at 10 DAF (days after flow
ering). At ten DAF, developing seeds contain very low
amounts of 10:0 (-2.5 mol%); the main fatty acids were 16:0
(-14 mol%), 18:1 (20 mol%), 18:2 (40-44 mol%), and 18:3
(18-20 mol%). The percent share of each fatty acid (16:0
through 20:1) in TFA in transgenic lines was similar to that of
wild type Camelina plants.
0038 FIG. 18B is a graph showing the fatty acid profile in
developing seeds from wild type and transgenic Camelina
lines expressing CvFatB1, CvFatB1+CpGAT1, or
CvFatB1+CvLPAT2+CplDGAT1 at 17 DAF. 17 DAF seeds
contain more medium-chain fatty acids (8:0 (4 mol%), 10:0
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(up to 24 mol %), 12:0 (2.5-4 mol %), 14:0 (3 mol%)) and
higher amounts of 16:0 (13 mol %) in transgenic lines. In
CvFatB1+CvLpat2+CpDGAT1, the amount of 18:1
decreases, while 18:2, 18:3 and 20:1 are present in amounts of
15 mol %, 16 mol % and 6 mol %, respectively, as compared
to 21.4 mol %, 30 mol % and 12.7 mol % in wild type
Camelina plants.
0039 FIG. 18C is a graph showing the fatty acid profile in
developing seeds from wild type and transgenic Camelina
lines expressing CvFatB1, CvFatB1+CpGAT1, or
CvFatB1+CvLPAT2+CpDGAT1 at 22 DAF. 22 DAF seeds
produce more medium chain fatty acids (5 mol% 8:0, 30 mol
% 10:0, 7 mol % (12:0-14:0)). The amounts of 16:0, 18:0,
18:1, 18:2, 18:3 and 20:1 in CvFatB1+CvLPAT2+CplDGAT1
line are 12 mol %, 8 mol %, 12 mol %, 16 mol %, and 5 mol

% as compared to 8 mol%. 13 mol%. 20 mol%. 41 mol %,
and 10 mol % in seeds of wild type plants. Thus, the total
share of 8:0 to 16:0 fatty acids in this line reaches 54 mol %
of TFA as compared to 39 mol % in CvFatB1 line, 43% in
CvFatB1+CpGAT1 line and just 8 mol % in wild type.
0040 FIG. 18D is a graph showing the fatty acid profile in
developing seeds from wild type and transgenic Camelina
lines expressing CvFatB1, CvFatB1+CpGAT1, or
CvFatB1+CvLPAT2+CplDGAT1 at 30 DAF. In 30 DAF seeds
from CvEatB1 line, there is 33.6 mol% of 8:0-16:0, 22.4 mol
% 18:1, 13.7 mol % 18:2, 16.0 mol % 18:3 and 6.6 mol %

20:1. CvFatB1+Cpl DGAT1 transgenic lines accumulate more
10:0, and 8:0-16:0 total fatty acid amount is 37 mol % while
amounts of 18:1, 18:2, 18:3 and 20:1 are similar to what is
found in seeds from CVFatB1 line. In CvPatE31+CvLPAT2+

CpGAT1 lines, the average share of 8:0-16:0 fatty acids is
43 mol % of TFA, 18.5 mol % being 10:0 and 13.2 mol %
18:1, 12.8 mol%. 18:2, 18.3 mol%. 18:3, 6.3 mol%. 20:1.

0041

FIG. 19 is a graph showing fatty acid profile of TAG

from N. benthamiana leaves infiltrated with CvPatB1,

CvFatB1+CpDGAT1, CvFatB1+AthlDGAT1.
0042 FIG. 20 is a graph showing DGAT activity in crude
extracts of developing seeds from Wt and transgenic Cam
elina lines. Values are meant-SD (n=3). Results are for assays
using 1-14C10:0-CoA, and diacylglycerol (DAG) species:
10:0/10:0 (1,2-didecanoyl-sn-glycerol) or 18:1/18:1 (1.2dioleoyl-sn-glycerol).
0043 FIG. 21 is a graph showing the seed weight of
mature seeds from Wt and transgenic Camelina.
0044 FIG. 22 is a graph showing the germination effi
ciency of transgenic Camelina seeds.
004.5 FIG. 23 is data showing 10:0/10:0 DAG containing
TAG species detected by Precursor 383.3 m/z ESI-MS/MS
SCaS.

0046 FIG. 24 are graphs showing fatty acid profiles of a
Camelina transgenic line.
DETAILED DESCRIPTION

0047. This disclosure is based on the discovery of novel
nucleic acids encoding acyltransferase polypeptides. Such
nucleic acids, SEQID NOs: 1, 3, 5, 7, or 9, and the polypep
tides encoded thereby, SEQ ID NOS: 2, 4, 6, 8, or 10, are
described and characterized herein. Based on this discovery,
Such nucleic acid sequences can be used to produce particular
and unique medium-chain fatty acids (MCFAS).
0048. As described herein, lysophosphatidic acid acyl
transferase (LPAT) and diacylglycerol acyltransferase
(DGAT) catalyze sequential reactions in the Kennedy path
way that produce triacylglycerols (TAG) in seeds and other

plant tissues and organs. Triacylglycerols are the principal
component of vegetable oils, which are used in a variety of
edible applications (e.g., baking, frying) as well as non-food
applications, such as biofuels, lubricants, and Surfactants.
LPAT uses fatty acids in the form of fatty acyl-Coenzyme A
(CoA) as substrates for esterification to the sn-2 position of
lysophosphatidic acid (LPA) to form phosphatidic acid (PA).
Following dephosphorylation of PA, the resulting diacylglyc
erol (DAG) serves as a substrate for addition of a fatty acid in
the form of fatty acyl-CoA to its sn-3 position to generate
triacylglycerol, via the activity of DGAT. LPAT activity in
seeds of the typical oilseed crops, such as canola (Brassica
napus), Camelina (Camelina sativa), and soybean (Glycine
max) have strong specificity for unsaturated C18 fatty acid
acyl-CoA substrates such as oleoyl (18:1)-, linoleoyl (18:2)and linolenoyl (18:3)-CoA, but little or no activity with satu
rated fatty acyl-CoA substrates (Sun et al., 1988, Plant
Physiol. 88, 56-60; Oo et al., 1989, Plant Physiol. 91, 1288
1295). This activity arises predominantly from LPATs of the
LPAT2 class, but also with contributions from LPATs of the

bacterial-type LPATB class Arroyo-Caro, J. M., Chileh, T.,

Kazachkov, M., Zou, J., Alonso, D. L., Garcia-Maroto, F.

(2013) Plant Sci. 199-200:29-40. The strict substrate speci
ficity of oilseed LPATs for unsaturated fatty acyl-CoA sub
strates represents a major bottleneck for metabolic engineer
ing of oilseeds to produce TAG with high levels of saturated
medium-chain fatty acids with C6-C14 chain-lengths for
applications such as biofuels, including bio-based Jet fuel A.
These metabolic engineering strategies typically involve
expression of divergent forms of the FatB acyl-ACP
thioesterase that are able to produce medium-chainfatty acids
of differing chain-lengths. An LPAT from coconut of the
LPATB class has been previously shown to be effective at
esterifying lauroyl (12:0)-CoA to the sn-2 position of LPA to
produce lauric acid-rich oils when co-expressed with a 12:0acyl carrier protein-specific FatB. The coconut LPATB
enzyme, however, was ineffective for esterification of CoA
forms of caprylic (8:0) or decanoic (10:0) acids to the LPA
Sn-2 position to generate 10:0-rich TAG in an engineered
oilseed (Wilberg et al., 2000, Planta, 212, 33-40). In addition,
no plant LPAT2 enzymes have been previously shown to have
significant activity with any saturated medium-chain fatty
acids.

0049 DGAT enzymes occur in two forms, DGAT1 and
DGAT2, based on their primary structures. These enzymes
also represent potential bottlenecks for the accumulation of
high levels of saturated medium-chain fatty acids in TAG of
engineered oilseeds. DGAT2 enzymes from plants such as
castor bean have been shown to enhance the accumulation of

modified fatty acids such as ricinoleic acid. However, no
specific plant DGAT1 or DGAT2 has been previously been
shown to be effective at promoting increased accumulation of
saturated medium-chain fatty acids in engineered oilseeds or
to be active with DAGs rich in medium-chain fatty acids such
as decanoic acid (10:0).
0050. The embodiment of this invention is the discovery of
LPAT2 and DGAT1 genes that are demonstrated in this dis
closure to enhance the accumulation of medium-chain fatty
acids, in particular, C8:0 and C10:0, in TAG and in the sn-2
position of TAG when expressed together with specialized
FatB genes in seeds of the oilseed crop camelina (Camelina
sativa). The co-expression of the LPAT2 genes with the
DGAT1 genes is also shown to yield synergistic increases in
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medium-chain fatty acid accumulation in TAG and the Sn-2
position of TAG in transgenic plants.
Nucleic Acids and Polypeptides
0051 Novel nucleic acids encoding acyltransferases are
provided herein (see, for example, SEQID NOs: 1, 3, 5, 7, or
9). Acyltransferases (PFO1553; EC 2.3.1) are well known in
the art and are defined as transferase enzymes that act on acyl
groups. The acyltransferases exemplified herein include a
lysophosphatidic acid acyltransferase (LPAT; EC 2.3.1.51)
and a diacylglycerol acyltransferase (DGAT; EC 2.3.1.20).
The LPAT2 and LPAT2a polypeptides disclosed herein are
unique in that they esterify saturated C8-C16 fatty acyl-CoA,
including a high affinity for saturated C8 and C10 fatty acyl
CoA, at the sn-2 position of triacylglycerols (TAGs), while
the DGAT1 polypeptides disclosed herein have unique speci
ficity for diacylglycerols (DAGs) Substrates having a satu
rated C10 and, to a lesser extent, a saturated C8, at the sn-2

position.
0052 Novel nucleic acids encoding medium-chain fatty
acid (MCFA)-specific thioesterase, FatB polypeptides also
are provided herein (see, for example, SEQID NO: 15). FatB
polypeptides are a class of thioesterases (EC 3.2.1.14) that
release C8 to C16 saturated fatty acids from acyl carrier
protein (ACP) during denovo fatty acid synthesis. The typical
FatB releases C16:0 from ACP, but FatBS that release other

saturated fatty acids are known.
0053 As used herein, nucleic acids can include DNA and
RNA, and includes nucleic acids that contain one or more
nucleotide analogs or backbone modifications. A nucleic acid
can be single Stranded or double stranded, which usually
depends upon its intended use. The novel nucleic acids pro
vided herein encode novel polypeptides (see, for example,
SEQID NOS: 2, 4, 6, 8, 10, or 16). Also provided are nucleic
acids and polypeptides that differ from SEQID NOs: 1, 3, 5,
7.9, or 15, and SEQID NOS: 2, 4, 6, 8, 10, or 16, respectively.
Nucleic acids and polypeptides that differ in sequence from
SEQID NOs: 1, 3, 5, 7, 9, or 15, and SEQID NOs: 2, 4, 6, 8,
10, or 16, can have at least 50% sequence identity (e.g., at

or more subject sequences, and aligns them so that identities,
similarities and differences can be determined. Gaps of one or
more residues can be inserted into a query sequence, a subject
sequence, or both, to maximize sequence alignments. Forfast
pairwise alignment of nucleic acid sequences, the default
parameters can be used (i.e., word size: 2; window size: 4;
scoring method: percentage; number oftop diagonals: 4; and
gap penalty: 5); for an alignment of multiple nucleic acid
sequences, the following parameters can be used: gap open
ing penalty: 10.0; gap extension penalty: 5.0; and weight
transitions: yes. For fast pairwise alignment of polypeptide
sequences, the following parameters can be used: word size:
1; window size: 5; scoring method: percentage; number oftop
diagonals: 5; and gap penalty: 3. For multiple alignment of
polypeptide sequences, the following parameters can be used:
weight matrix: blosum: gap opening penalty: 10.0; gap exten
sion penalty: 0.05; hydrophilic gaps: on; hydrophilic resi
dues: Gly, Pro, Ser, ASn, Asp, Gln, Glu, Arg, and Lys; and
residue-specific gap penalties: on. ClustalW can be run, for
example, at the Baylor College of Medicine Search Launcher
website or at the European Bioinformatics Institute website
on the World WideWeb.

0056 Changes can be introduced into a nucleic acid mol
ecule (e.g., SEQID NOs: 1, 3, 5, 7, 9, or 15), thereby leading
to changes in the amino acid sequence of the encoded
polypeptide (e.g., SEQ ID NOS: 2, 4, 6, 8, 10, or 16). For
example, changes can be introduced into nucleic acid coding
sequences using mutagenesis (e.g., site-directed mutagen
esis, PCR-mediated mutagenesis) or by chemically synthe
sizing a nucleic acid molecule having Such changes. Such
nucleic acid changes can lead to conservative and/or non
conservative amino acid Substitutions at one or more amino
acid residues. A "conservative amino acid Substitution' is one

in which one amino acid residue is replaced with a different
amino acid residue having a similar side chain (see, for
example, Dayhoff et al. (1978, in Atlas of Protein Sequence
and Structure, 5(Suppl. 3):345-352), which provides fre
quency tables for amino acid Substitutions), and a non-con
servative Substitution is one in which an amino acid residue is

least 55%, 60%, 65%, 70%, 75%, 80%, 81%, 82%, 83%,
84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,

replaced with an amino acid residue that does not have a

94%. 95%, 96%, 97%, 98%, or 99% sequence identity) to
SEQID NOs: 1, 3, 5, 7, 9, or 15, and SEQID NOs: 2, 4, 6, 8,
10, or 16, respectively.
0054. In calculating percent sequence identity, two
sequences are aligned and the number of identical matches of

0057. As used herein, an "isolated nucleic acid molecule
is a nucleic acid molecule that is free of sequences that natu
rally flank one or both ends of the nucleic acid in the genome
of the organism from which the isolated nucleic acid mol
ecule is derived (e.g., a cDNA or genomic DNA fragment
produced by PCR or restriction endonuclease digestion).
Such an isolated nucleic acid molecule is generally intro
duced into a vector (e.g., a cloning vector, or an expression
vector) for convenience of manipulation or to generate a

nucleotides or amino acid residues between the two

sequences is determined. The number of identical matches is
divided by the length of the aligned region (i.e., the number of
aligned nucleotides oramino acid residues) and multiplied by
100 to arrive at a percent sequence identity value. It will be
appreciated that the length of the aligned region can be a
portion of one or both sequences up to the full-length size of
the shortest sequence. It also will be appreciated that a single
sequence can align with more than one other sequence and
hence, can have different percent sequence identity values
over each aligned region.
0055. The alignment of two or more sequences to deter
mine percent sequence identity can be performed using the
computer program ClustalW and default parameters, which
allows alignments of nucleic acid or polypeptide sequences to
be carried out across their entire length (global alignment).
Chenna et al., 2003, Nucleic Acids Res., 31 (13):3497-500.
ClustalW calculates the best match between a query and one

similar side chain.

fusion nucleic acid molecule, discussed in more detail below.
In addition, an isolated nucleic acid molecule can include an

engineered nucleic acid molecule Such as a recombinant or a
synthetic nucleic acid molecule.
0.058 As used herein, a “purified polypeptide is a
polypeptide that has been separated or purified from cellular
components that naturally accompany it. Typically, the
polypeptide is considered “purified when it is at least 70%
(e.g., at least 75%, 80%, 85%, 90%. 95%, or 99%) by dry
weight, free from the polypeptides and naturally occurring
molecules with which it is naturally associated. Since a
polypeptide that is chemically synthesized is, by nature, sepa
rated from the components that naturally accompany it, a
synthetic polypeptide is “purified.”
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0059 Nucleic acids can be isolated using techniques rou
tine in the art. For example, nucleic acids can be isolated using
any method including, without limitation, recombinant
nucleic acid technology, and/or the polymerase chain reaction
(PCR). General PCR techniques are described, for example in
PCR Primer: A Laboratory Manual, Dieffenbach & Dveksler,
Eds. Cold Spring Harbor Laboratory Press, 1995. Recombi
nant nucleic acid techniques include, for example, restriction
enzyme digestion and ligation, which can be used to isolate a
nucleic acid. Isolated nucleic acids also can be chemically
synthesized, either as a single nucleic acid molecule or as a
series of oligonucleotides.
0060 Polypeptides can be purified from natural sources
(e.g., a biological sample) by known methods such as DEAE
ion exchange, gel filtration, and hydroxyapatite chromatog
raphy. A polypeptide also can be purified, for example, by
expressing a nucleic acid in an expression vector. In addition,
a purified polypeptide can be obtained by chemical synthesis.
The extent of purity of a polypeptide can be measured using
any appropriate method, e.g., column chromatography, poly
acrylamide gel electrophoresis, or HPLC analysis.
0061 A vector or construct containing a nucleic acid (e.g.,
a nucleic acid that encodes a polypeptide) also is provided.
Vectors, including expression vectors, are commercially
available or can be produced by recombinant DNA tech
niques routine in the art. A vector containing a nucleic acid
can have expression elements operably linked to Such a
nucleic acid, and further can include sequences such as those
encoding a selectable marker (e.g., an antibiotic resistance
gene). A vector containing a nucleic acid can encode a chi
meric or fusion polypeptide (i.e., a polypeptide operatively
linked to a heterologous polypeptide, which can be at either
the N-terminus or C-terminus of the polypeptide). Represen
tative heterologous polypeptides are those that can be used in
purification of the encoded polypeptide (e.g., 6xHis tag, glu
tathione S-transferase (GST))
0062 Expression elements include nucleic acid sequences
that direct and regulate expression of nucleic acid coding
sequences. One example of an expression element is a pro
moter sequence. Expression elements also can include
introns, enhancer sequences, response elements, or inducible
elements that modulate expression of a nucleic acid. Expres
sion elements can be of bacterial, yeast, insect, mammalian,
or viral origin, and vectors can contain a combination of
elements from different origins. As used herein, operably
linked means that a promoter or other expression element(s)
are positioned in a vector relative to a nucleic acid in Such a
way as to direct or regulate expression of the nucleic acid
(e.g., in-frame).
0063 Vectors as described herein can be introduced into a
host cell. As used herein, “host cell refers to the particular

0064. Nucleic acids can be detected using any number of
amplification techniques (see, e.g., PCR Primer: A Labora
tory Manual, 1995, Dieffenbach & Dveksler, Eds. Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.:
and U.S. Pat. Nos. 4,683, 195; 4,683.202; 4,800,159; and

4.965.188) with an appropriate pair of oligonucleotides (e.g.,
primers). A number of modifications to the original PCR have
been developed and can be used to detect a nucleic acid.
0065 Nucleic acids also can be detected using hybridiza
tion. Hybridization between nucleic acids is discussed in
detail in Sambrook et al. (1989, Molecular Cloning: A Labo
ratory Manual, 2nd Ed., Cold Spring Harbor Laboratory
Press, Cold Spring Harbor, N.Y.; Sections 7.37-7.57, 9.47-9.
57, 11.7-11.8, and 11.45-11.57). Sambrook et al. discloses
suitable Southern blot conditions for oligonucleotide probes
less than about 100 nucleotides (Sections 11.45-11.46). The
Tm between a sequence that is less than 100 nucleotides in
length and a second sequence can be calculated using the
formula provided in Section 11.46. Sambrook et al. addition
ally discloses Southern blot conditions for oligonucleotide
probes greater than about 100 nucleotides (see Sections 9.47
9.54). The Tm between a sequence greater than 100 nucle
otides in length and a second sequence can be calculated
using the formula provided in Sections 9.50-9.51 of Sam
brook et al.

0066. The conditions under which membranes containing
nucleic acids are prehybridized and hybridized, as well as the
conditions under which membranes containing nucleic acids
are washed to remove excess and non-specifically bound
probe, can play a significant role in the stringency of the
hybridization. Such hybridizations and washes can be per
formed, where appropriate, under moderate or high Strin
gency conditions. For example, washing conditions can be
made more stringent by decreasing the salt concentration in
the wash Solutions and/or by increasing the temperature at
which the washes are performed. Simply by way of example,
high Stringency conditions typically include a wash of the
membranes in 0.2XSSC at 65° C.

0067. In addition, interpreting the amount of hybridization
can be affected, for example, by the specific activity of the
labeled oligonucleotide probe, by the number of probe-bind
ing sites on the template nucleic acid to which the probe has
hybridized, and by the amount of exposure of an autoradio
graph or other detection medium. It will be readily appreci
ated by those of ordinary skill in the art that although any
number of hybridization and washing conditions can be used
to examine hybridization of a probe nucleic acid molecule to
immobilized target nucleic acids, it is more important to
examine hybridization of a probe to target nucleic acids under
identical hybridization, washing, and exposure conditions.
Preferably, the target nucleic acids are on the same mem

cell into which the nucleic acid is introduced and also

brane.

includes the progeny of such a cell that carry the vector. A host
cell can be any prokaryotic or eukaryotic cell. For example,
nucleic acids can be expressed in bacterial cells such as E.
coli, or in insect cells, yeast or mammalian cells (such as
Chinese hamster ovary cells (CHO) or COS cells). Other
suitable host cells are known to those skilled in the art. Many
methods for introducing nucleic acids into host cells, both in

0068 A nucleic acid molecule is deemed to hybridize to a
nucleic acid but not to another nucleic acid if hybridization to
a nucleic acid is at least 5-fold (e.g., at least 6-fold, 7-fold,
8-fold, 9-fold, 10-fold, 20-fold, 50-fold, or 100-fold) greater
than hybridization to another nucleic acid. The amount of
hybridization can be quantitated directly on a membrane or
from an autoradiograph using, for example, a Phosphorm
ager or a Densitometer (Molecular Dynamics, Sunnyvale,
Calif.).
0069 Polypeptides can be detected using antibodies.
Techniques for detecting polypeptides using antibodies
include enzyme linked immunosorbent assays (ELISAS),

vivo and in vitro, are well knownto those skilled in the art and

include, without limitation, electroporation, calcium phos
phate precipitation, polyethylene glycol (PEG) transforma
tion, heat shock, lipofection, microinjection, and viral-medi
ated nucleic acid transfer.
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Western blots, immunoprecipitations and immunofluores
cence. An antibody can be polyclonal or monoclonal. An
antibody having specific binding affinity for a polypeptide
can be generated using methods well known in the art. The
antibody can be attached to a solid Support Such as a micro
titer plate using methods known in the art. In the presence of
a polypeptide, an antibody-polypeptide complex is formed.
0070 Detection (e.g., of an amplification product, a
hybridization complex, or a polypeptide) is usually accom
plished using detectable labels. The term “label' is intended
to encompass the use of direct labels as well as indirect labels.
Detectable labels include enzymes, prosthetic groups, fluo
rescent materials, luminescent materials, bioluminescent
materials, and radioactive materials.

Medium-Chain Fatty Acids and Methods of Making
Medium-Chain Fatty Acids
0071. The nucleic acids described herein, and the
polypeptides encoded thereby, can be used to engineer a
variety of useful medium-chain fatty acids and triacylglycer
ols that incorporate Such medium-chain fatty acids. As used
herein, medium-chain fatty acids refer to 6- to 14-carbon long
saturated fatty acids; specifically, caprioc (C6:0), caprylic
(C8:0), capric (C10:0), lauric (C12:0), and myristic (C14:0)
acids. Coconut and palm-kernel oils naturally contain high
amounts of medium-chain fatty acids. Medium-chain tria
cylglycerols (MCTs) usually contain unsaturated 6- to
14-carbon fatty acid esters of glycerol, but the nucleic acids
described herein and the polypeptides encoded thereby can be
used to produce TAGs containing predominantly C8:0, C10:
0, or C12:0 fatty acid esters at the sn-2 position. As used
herein, “predominantly refers to at least 20% of the TAGs
(e.g., at least 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%,
90% or 95% of the TAGs) having a C8:0 or a C10:0 at the sn-2
position.
0072 For example, FatBs that can generate C8 and C10
fatty acids (e.g., ChFatB2 or CvFatB1) can be used in com
bination with at least one of the novel acyltransferases
described herein to strongly enhance the production of TAGs
having a saturated C8 or C10 at the sn-2 position. Also for
example, a FatB that can generate C14 and C16 fatty acids
(e.g., Cpfath32) can be used in combination with at least one
of the novel acyltransferases described herein to strongly
enhance the production of TAGs having a saturated C14 or
C16 at the sn-2 position. It would be appreciated that other
FatB sequences can be used in combination with at least one
of the acyltransferases described herein to engineer useful
medium-chain fatty acids and the TAGs incorporating them.
0073. Significantly, the LPATs and DGATs described
herein have unprecedented specificity for C8 and C10 fatty
acids. Also significantly, the combination of one of the LPAT
sequences disclosed herein and one of the DGAT sequences
disclosed herein, in combination with a FatB sequence,
results in a synergistic effect on the production of fatty acids
and, consequently, the TAGs incorporating Such fatty acids.
Although not wishing to be bound by any particular mecha
nism, the observed synergy likely is because the LPATs
described herein generate higher levels of DAGs with satu
rated fatty acids at the sn-2 position, which likely is the
preferred substrate for DGATs described herein.
0074 At least one of the acyltransferase sequences
described herein can be expressed (e.g., overexpressed) in a
transgenic organism in order to produce oils or triacylglycer
ols one or more medium-chain fatty acids. Therefore, trans

genic organisms are provided that are transformed with at
least one of the acyltransferase nucleic acid molecules
described herein (e.g., SEQ ID NOs: 1, 3, 5, 7, or 9) or a
functional fragment thereof, under control of a promoter that
is able to drive expression. As discussed herein, a nucleic acid
molecule used in a plant expression vector can have a differ
ent sequence than a sequence described herein, which can be
expressed as a percent sequence identity (relative to, e.g.,
SEQID NOs: 1, 3, 5, 7, or 9) or based on the conditions under
which the sequence hybridizes to, e.g., SEQID NOs: 1, 3, 5,
7, or 9.

0075. As an alternative to using a full-length sequence, a
portion of the sequence can be used that encodes a polypep
tide fragment having the desired functionality (referred to
hereinas a “functional fragment'). When used with respect to
nucleic acids, it would be appreciated that it is not the nucleic
acid fragment that possesses functionality but the encoded
polypeptide fragment. Based on the disclosure herein, one of
skill in the art can predict the portion(s) of a polypeptide (e.g.,
one or more domains) that may impart the desired function
ality.
0076. In addition to at least one of the acyltransferases
disclosed herein, the organisms also can contain a nucleic
acid encoding a MCFA-specific thioesterase (FatB). Numer
ous FatB sequences are known in the art (e.g., without limi
tation, SEQID NOs: 11 and 13), or the novel FatB sequence
disclosed herein (e.g., SEQID NO:15) can be used. In some
embodiments, the FatB sequence is heterologous to the
organism; in some embodiments, the FatB sequence is endog
enous to the organism.
0077 Methods of introducing one or more nucleic acids
(e.g., one or more heterologous nucleic acids, one or more
transgenes) into cells, including plant cells, are known in the
art and include, for example, particle bombardment, Agro
bacterium-mediated transformation, microinjection, poly
ethylene glycol-mediated transformation (e.g., of proto
plasts, see, for example, Yoo et al. (2007, Nature Protocols,
2(7): 1565-72)), liposome-mediated DNA uptake, or elec
troporation. Following transformation of plant cells, the
transgenic cells can be regenerated into transgenic plants. As
described herein, expression of the transgene results in an
organism that produces, or exhibits an increased amount of
medium-chain fatty acids (relative to a corresponding organ
ism not containing or not expressing the transgene). The
transgenic organisms can be screened for the amount of
medium-chain fatty acids, and the medium-chain fatty acids
can be obtained (e.g., purified) from the organism.
0078 Methods of detecting medium-chain fatty acids, and
methods of determining the amount of one or more medium
chain fatty acids, are known in the art and are described
herein. For example, high performance liquid chromatogra
phy (HPLC), gas liquid chromatography (GLC), liquid chro
matography (LC), and ESI-MS/MS scans can be used to
detect the presence of one or more medium-chain fatty acids
and/or determine the amount of one or more medium-chain

fatty acids. Lipase digestion of triacylglycerols can also be
used to establish the content of medium-chain fatty acids at
the Sn-2 position of triacylglycerols.
0079. As used herein, an “increase' refers to an increase
(e.g., a statistically significant increase) in the amount of
medium-chain fatty acids or oils or triacylglycerols in plants
by at least about 5% up to about 95% (e.g., about 5% to about
10%, about 5% to about 20%, about 5% to about 50%, about
5% to about 75%, about 10% to about 25%, about 10% to
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about 50%, about 10% to about 90%, about 20% to about
40%, about 20% to about 60%, about 20% to about 80%,
about 25% to about 75%, about 50% to about 75%, about 50%
to about 85%, about 50% to about 95%, and about 75% to

about 95%) relative to the amount from a non-transgenic
organism. As used herein, statistical significance refers to a
p-value of less than 0.05, e.g., a p-value of less than 0.025 or
a p-value of less than 0.01, using an appropriate measure of
statistical significance, e.g., a one-tailed two sample t-test.
0080 When the organism is a microbe, a highly express
ing or constitutive promoter can be used to direct expression
of the at least one acyltransferase. Transgenic microbes then
can be cultured or fermented in order to obtain the medium

chain fatty acids. When the organism is a plant, it generally is
desirable, although not absolutely required, to use a seed
specific promoter to direct expression of the at least one
acyltransferase. Significantly, the promoters of the acyltrans
ferases described herein are seed-specific, and thus, can be
used to direct expression of the sequences in a transgenic
plant. Transgenic plants having increased amounts of
medium-chain fatty acids, compared to the amount in a cor
responding non-transgenic plant, can be selected for use in,
for example, a breeding program as discussed in more detail
below.

0081 Following transformation, transgenic To plants are
regenerated from the transformed cells and those plants, or a
Subsequent generation of that population (e.g., T. T. T.
etc.), can be screened for the presence of the at least one
acyltransferase (e.g., SEQID NOs: 1, 3, 5, 7, or 9) or for the
phenotype (e.g., an increase in the amount of medium-chain
fatty acids compared to a non-transgenic plant or a transgenic
plant not expressing the transgene). Screening for plants car
rying at least one acyltransferase can be performed using
methods routine in the art (e.g., hybridization, amplification,
combinations thereof) or by evaluating the phenotype (e.g.,
detecting and/or determining the amount of one or more
medium-chain fatty acids in the plant (e.g., in the seed)).
Generally, the presence and expression of the at least one
acyltransferase (e.g., SEQID NOs: 1, 3, 5, 7, or 9) results in
an increase of one or more medium-chain fatty acids in the
plants (e.g., in seeds from the plants) compared to a corre
sponding plant (e.g., having the same varietal background)
lacking or not expressing the at least one acyltransferase.
0082. A plant carrying the at least one acyltransferase
(e.g., SEQ ID NOs: 1, 3, 5, 7, or 9) can be used in a plant
breeding program to create novel and useful cultivars, lines,
varieties and hybrids. Thus, in some embodiments, a T, T
T or later generation plant containing the at least one acyl
transferase is crossed with a second plant, and progeny of the
cross are identified in which the at least one acyltransferase is
present. It will be appreciated that the second plant can be one
of the species and varieties described herein. It will also be
appreciated that the second plant can contain the same trans
gene or combination of transgenes as the plant to which it is
crossed, a different transgene, or the second plant can carry a
mutation or be wild type at the endogenous locus. Addition
ally or alternatively, a second line can exhibit a phenotypic
trait such as, for example, disease resistance, high yield,
height, plant maturation, stalk size, and/or leaf number per
plant.
0083) Breeding is carried out using known procedures.
DNA fingerprinting, SNP or similar technologies may be
used in a marker-assisted selection (MAS) breeding program
to transfer or breed the transgene(s) into other lines, varieties
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or cultivars, as described herein. Progeny of the cross can be
screened for the transgene(s) using methods described herein,
and plants having the transgenes described herein (e.g., SEQ
ID NOs: 1, 3, 5, 7, or 9) can be selected. For example, plants
in the F or backcross generations can be screened using a
marker developed from a sequence described herein or a
fragment thereof, using one of the techniques listed herein.
Seed from progeny plants also can be screened for the amount
of one or more medium-chain fatty acids, and those plants
having increased amounts, compared to a corresponding
plant that lacks the transgene, can be selected. Plants identi
fied as possessing the transgene and/or the expected pheno
type can be backcrossed or self-pollinated to create a second
population to be screened. Backcrossing or other breeding
procedures can be repeated until the desired phenotype of the
recurrent parent is recovered.
I0084. Successful crosses yield F plants that are fertile and
that can be backcrossed with one of the parents if desired. In
some embodiments, a plant population in the F generation is
screened for the transgene using standard methods (e.g., PCR
with primers based upon the nucleic acid sequences disclosed
herein). Selected plants are then crossed with one of the
parents and the first backcross (BC) generation plants are
self-pollinated to produce a BCF population that is again
screened for the transgene or the phenotype. The process of
backcrossing, self-pollination, and screening is repeated, for
example, at least four times until the final Screening produces
a plant that is fertile and reasonably similar to the recurrent
parent. This plant, if desired, is self-pollinated and the prog
eny are Subsequently screened again to confirm that the plant
contains the transgene and exhibits the expected phenotype.
Breeder's seed of the selected plant can be produced using
standard methods including, for example, field testing, con
firmation of the presence of the transgene, and/or chemical
analyses of the plant (e.g., of the seed) to determine the level
of medium-chain fatty acids.
I0085. The result of a plant breeding program using the
transgenic plants described herein are novel and useful culti
vars, varieties, lines, and hybrids. As used herein, the term
“variety” refers to a population of plants that share constant
characteristics which separate them from other plants of the
same species. A variety is often, although not always, sold
commercially. While possessing one or more distinctive
traits, a variety is further characterized by a very small overall
variation between individuals within that variety. A "pure
line' variety may be created by several generations of self
pollination and selection, or vegetative propagation from a
single parent using tissue or cell culture techniques. A "line.”
as distinguished from a variety, most often denotes a group of
plants used non-commercially, for example, in plant research.
A line typically displays little overall variation between indi
viduals for one or more traits of interest, although there may
be some variation between individuals for other traits.

I0086 A variety can be essentially derived from another
line or variety. As defined by the International Convention for
the Protection of New Varieties of Plants (Dec. 2, 1961, as
revised at Geneva on Nov. 10, 1972. On Oct. 23, 1978, and on

Mar. 19, 1991), a variety is “essentially derived from an
initial variety if: a) it is predominantly derived from the initial
variety, or from a variety that is predominantly derived from
the initial variety, while retaining the expression of the essen
tial characteristics that result from the genotype or combina
tion of genotypes of the initial variety; b) it is clearly distin
guishable from the initial variety; and c) except for the
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differences which result from the act of derivation, it confirms

to the initial variety in the expression of the essential charac
teristics that result from the genotype or combination of geno
types of the initial variety. Essentially derived varieties can be
obtained, for example, by the selection of a natural or induced
mutant, a Somaclonal variant, a variant individual plant from
the initial variety, backcrossing, or transformation.
0087 Hybrids can be produced by preventing self-polli
nation of female parent plants (i.e., seed parents) of a first
variety, permitting pollen from male parent plants of a second
variety to fertilize the female parent plants, and allowing F
hybrid seeds to form on the female plants. Self-pollination of
female plants can be prevented by emasculating the flowers at
an early stage of flower development. Alternatively, pollen
formation can be prevented on the female parent plants using
a form of male sterility. For example, male sterility can be
produced by cytoplasmic male sterility (CMS), nuclear male
sterility, genetic male sterility, molecular male sterility
wherein a transgene inhibits microsporogenesis and/or pollen
formation, or self-incompatibility. Female parent plants con
taining CMS are particularly useful. In embodiments in
which the female parent plants are CMS, the male parent
plants typically contain a fertility restorer gene to ensure that
the F hybrids are fertile. In other embodiments in which the
female parents are CMS, male parents can be used that do not
contain a fertility restorer. F hybrids produced from such
parents are male sterile. Male sterile hybrid seed can be
interplanted with male fertile seed to provide pollen for seed
set on the resulting male sterile plants.
0088 Varieties, lines and cultivars described herein can be
used to form single-cross F hybrids. In such embodiments,
the plants of the parent varieties can be grown as Substantially
homogeneous adjoining populations to facilitate natural
cross-pollination from the male parent plants to the female
parent plants. The F seed formed on the female parent plants
is selectively harvested by conventional means. One also can
grow the two parent plant varieties in bulk and harvestablend
of F hybrid seed formed on the female parent and seed
formed upon the male parent as the result of self-pollination.
Alternatively, three-way crosses can be carried out wherein a
single-cross F hybrid is used as a female parent and is
crossed with a different male parent. As another alternative,
double-cross hybrids can be created wherein the F progeny
of two different single-crosses are themselves crossed. Self
incompatibility can be used to particular advantage to prevent
self-pollination of female parents when forming a double
cross hybrid.
0089. The microbial organisms used in the methods
described herein include, without limitation, bacteria (E. coli,
Pseudomonas sp.), cyanobacteria (Synechocystis sp), and
green microalgae (C. reinhardtii, Phaeodactylum tricornu
tum, Chlorella sp., Nannochloropsis sp.) species, fungal (Yar
rowia lipolytica, Saccharomyces cerevisiae) species. The
plants used in the methods described herein can be oilseed
plants such as, without limitation, Camelina spp. (e.g., Cam
elina sativa, Camelina alyssum, Camelina rumelica) or other
Brassicaceae spp. (e.g., Brassica oleracea, Brassica rapa,
Brassica napus, B. Carinata), Limnanthes alba (meadow
foam), Glycine max (soybean), Linum spp. (e.g., Linum usi
tatissimum, flax), Crambe spp. (e.g. Crambe abyssinica),
Ricinus communis (castor bean), Gossypium spp. (e.g. Gos
sypium hirsutum cotton), or non-oilseed plants such as, with
out limitation, legumes (e.g., peas, beans), tuberous crops
(potato, cassava), or other crop plant.

(0090. The MCFAS or TAGs comprising MCFAs produced
in the methods herein can be used in any number of products
in which a medium-chain fatty acid or a TAG containing Such
a medium-chain fatty acid is desired. Such products include,
without limitation, biofuel and/or jet fuel. For example, veg
etable oils with TAGs containing fatty acid chains having 10
or less carbons are more desirable feedstocks for the biofuel

industry due to their lower viscosity and because such veg
etable oils may not require trans-esterification, which is usu
ally a required step when converting vegetable oils to biodie
sel. In addition, the MCFAS or the TAGs comprising MCFAs
produced as described herein can be used in detergents, cos
metics, Surfactants, or feedstocks for preparation of other
specialized chemicals.
0091. In addition, in some embodiments, one or more of
the acyltransferases described herein can be used in industrial
inter-esterification of fatty acids to generate particular TAGs
or one or more of the acyltransferases described herein can be
used in a bioreactor (e.g., one or more of the acyltransferases
described herein can be immobilized) to make particular
TAGs for specialized nutritional or industrial applications.
0092. In accordance with the present invention, there may
be employed conventional molecular biology, microbiology,
biochemical, and recombinant DNA techniques within the
skill of the art. Such techniques are explained fully in the
literature. The invention will be further described in the fol

lowing examples, which do not limit the scope of the methods
and compositions of matter described in the claims.
EXAMPLES
Part A

Example 1
Plant Material, Growth and Transformation
Conditions

I0093 Camelina sativa seed was sowed into 81 cm square

green plastic pots with Fafard Germination Mix based soil.
Natural ambient light was Supplemented in the greenhouses
with a combination of metal halide and high pressure Sodium
lights. Lights was provided for a 14 hour day-length. During
the daytime temperatures were set at a range of 24°C.-26°C.
and during the nighttime temperatures were set at a range 18'
C.-20° C. When outdoor temperatures were above 29° C. the
supplemental lights were shut off to reduce the need for extra
cooling. Agrobacterium tumefaciens cells (strain C58C1)
were transformed with the binary vectors containing LPAT
cDNA by the electroporation. Camelina plants were trans
formed by floral dip followed by vacuum infiltration and a
fluorescent protein (Dsked) was used as a visual selection
marker (Lu & Kang, 2008, Plant Cell Rep. 27:273-8). Seg
regation analyses were performed on the T2 showed fluores
cence seeds to determine the number of T-DNA insertion loci.

Plants homozygous for the transgene were identified by
screening T3 seeds for 100% red fluorescence.
Example 2
RNA Isolation from Cuphea Species and cDNA
Conversion

(0094) Total RNAs were isolated from different Cuphea
tissues such as roots, stems, leaves, flowers and developing
seeds using slightly modified methods described in the pre
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vious report (Chang et al., 1993, Plant Mol. Biol. Report.
11:113-6) and RNeasy Plant Mini Kit (Qiagen). The first step
was performed by the CTAB-based procedure. A pre-heated
10 ml of extraction buffer (2% w/v CTAB, 2% w/v PVP, 2 M
NaCl, 100 mM Tris-HCl pH 8.0, 25 mM EDTA pH 8.0 and
0.05% w/v of spermidine) was added to the sample (200-300
mg) ground in liquid nitrogen, mixed vigorously by Vortexing
and incubated at 65° C. for 10 min. The sample was divided
into several new microcentrifuge tubes. An equal Volume of
chloroform was added and the tubes, mixed vigorously and
then centrifuged at 13,000 rpm for 10 min at 4° C. The
Supernatant was transferred to new microcentrifuge tubes and
!/3 volume of 8 MLiCl was added. The mixture was incubated

in ice for overnight, and the RNA was selectively collected
after centrifugation at 13000 rpm for 1 hour at 4°C. The pellet
was resuspended in 500 ul of RLT buffer in RNeasy Plant
Mini Kit and was then carried out as indicated in the manu

facturers handbook including DNase I treatment. The first
strand cDNA was synthesized from 2 ug total RNA using
RevertAid First Strand cDNA Synthesis Kit (Thermo Scien
tific) with oligo-(dT) primer.
Example 3
Confocal Laser Scanning Microscope
0095. The expression of transient fluorescent fusion pro
teins in tobacco leaves was performed using the agro-infiltra
tion methods as described previously (Sparkes et al., 2006,
Nature Protocols, 1:2019-25). Two days after infiltration, the
abaxial leaf surface was observed with a confocal laser scan

ning microscope (Olympus). ForYFP and mCherry, the exci
tation wavelengths were respectively 488 nm and 545 nm,
and the emitted fluorescence was collected at 495-530 nm.

lent Technologies 7890A gas chromatograph (GC) fitted with
a 30 m length}x0.25 mm inner diameter HP-INNOWax col
umn (Agilent, Santa Clara, Calif., USA) using H2 carrier gas.
The GC was programmed for an initial temperature of 90° C.
(1 minhold) followed by an increase of 30° C. min-1 to 235°
C. and maintained for a further 5 min. Detection was achieved

using flame ionization.
Example 6
Neutral Loss ESI-MS/MS Analysis
0098. Mass spectrometry analyses were conducted using
an Applied Biosystems (Foster City, Calif.) 4000 QTRAP
linear ion trap quadrupole mass spectrometer to characterize
TAG molecular species. The total neutral lipid extract for
ESI-MS/MS analysis was prepared as described for seed oil
content measurement below but without added internal stan

dard and diluted 1:5000 in waterfisopropyl alcohol/methanol
(55:35:10 V/v/v) containing 25 mm ammonium formate and 4
LL/L formic acid and directly infused into the mass spectrom
eter at a rate of 20 Jul per minute. Instrument settings were as
follows: Source temperature 400°C., ESI needle voltage 5.5
kV (positive mode), desolvation potential (DP) 90, entrance
potential (EP) 10, Curtain gas (CUR) 10, and gas 1 (GS1) 50
arbitrary units, gas 2 (GS2) 40 arbitrary units. Neutral loss
spectra showing the loss of a specific fatty acid from TAG
species were generated by monitoring the loss of 189.1 m/z.
(for C10:0) and 245.1 m/z (for C14:0). Scans were taken over
a mass range of 500-1475 m/z, with a cycle time of 3 s. Data
was collected for five cycles.
Example 7

and 565-600 nm, respectively.
Example 4
Complementation of Cuphea LPAT cDNAs by
Expression in Escherichia coli Mutant
0096. The thermo-sensitive strain, E. coli JC201, was used
to complement the deficient of LPAT activity (Coleman,
1992, Mol. Gen. Genet., 232:295-303). The Cuphea LPAT
cDNAs were cloned into the into the pBluescript SK multi
cloning site using SacI and Not. JC201 was transformed via
heat shock and was selected on amplicillin plates at 30° C.
Complementing colonies were inoculated into starter cultures
and grown to an optical density at 600 nm of 0.5 at 30°C. with
or without 1 mM isopropylthio-f-galactoside (IPTG). Ali
quots were grown in the presence of IPTG at 30° C. and 44
C., and growth curves were constructed using data obtained
from three individual complementation experiments.
Example 5
Fatty Acid Analysis of Seed Oils
0097. Fatty acid methyl esters (FAMEs) were generated
by grinding 10 mg of dry seeds in 2 mL of 2.5% H2SO4 (v/v)
in methanol including 900 ug of tri 17:0-TAG (Nu-Chek Prep,
Elysian, Minn., USA) in toluene (10 mg/mL) as an internal
standard and heated for 45 min at 90° C. in tightly capped
tubes. Following cooling, 1.5 mL of water and 1.5 mL hexane
were added to tubes and mixed vigorously. The organic phase
was transferred to autosampler vials and analyzed on an Agi

RNA. Isolation from Developing Seeds and cDNA
Library Construction
0099 Total RNA was isolated from Cuphea pulcherrima
and Cuphea Viscosleaves and developing seeds collected
from greenhouse grown plants and immediately frozen in
liquid nitrogen and stored at -80°C. until use in RNA isola
tion. Total RNA was isolated according to a method described
previously (Mattheus et al., 2003, Phytochemical Analysis,
14:209-15; Suzuki et al., 2004, Biotechniques, 37:542-44). In
brief, developing seeds were grounded to a fine powder in
liquid nitrogen. The powders were transferred to a chilled
centrifuge tube containing cold extraction buffer consisting
of 100 mM Tris-HCl, pH 8.0, 50 mMethylenebis (oxyethyl
enenitrilo) tetraacetic acid, pH 8.0, 100 mM sodium chloride,
1% 6-(p-toluidino)-2-naphthalenesulphonic acid, 6% sodium
p-aminosalicylic acid, 1% SDS, 1% PVP-40, 3% PVPP:chlo
roform and 1% B-mercaptoethanol. The sample was centri
fuged for 10 min with Sorvall SS-34 rotor, 10500 rpm at 4°C.
The Supernatant was transferred to a fresh tube. An equal
Volume of chloroform was added and the mixture was Vor

texed for 2 min, centrifuged for 10 min at 10500 rpm and 4°
C. The aqueous phase was transferred to a fresh tube. The
aqueous fraction was extracted twice with phenol: chloroform
(1:1, V/v), and extracted once with chloroform. The RNA was
precipitated overnight with 0.1 volume of 3M sodium acetate
(pH 5.2) and 2.5 volume of 95% ethanol at -20°C. The RNA
was precipitated by centrifugation for 30 min at 10500 rpm
and 4° C. rinsed once with 70% ethanol, briefly dried, and
dissolved in DEPC-water.
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Example 8-454
Transcriptome Analysis
0100 200 ng of polyA+-enriched RNA prepared from
developing seeds of Cuphea pulcherrima and Cuphea visco
Sissma was used in the preparation of a single sequencing
library with custom adaptors according to methods of
Nguyen, H.T., Silva, J. E., Podicheti, R., Macrander, J., Yang,
W., Nazarenus, T. J., Nam, J. W., Jaworski, J. G., Lu, C,

Scheffler, B. E., Mockaitis, K & Cahoon, E. B. (2013). The
double-stranded cDNA library intermediate was partially
normalized by DSN treatment (Evrogen) to reduce the rep
resentation of the transcripts of greatest abundance. Shearing
prior to adaptor ligation was by nebulization (30 sec. 30 psi).
The final library was assessed on a Bioanalyzer DNA7500
chip (Agilent) and showed a peak size of 660 bp.
0101 Emulsion PCR and sequencing was done according
to the manufacturer (Rochef.454 Sequencing). Two regions of
two-region plus three regions of four-region GS-FLX Tita
nium Pico TitreTM plate were run to 800 cycles.
0102 The Cuphea pulcherrima and Cuphea viscosissma
transcriptome assemblies were matched by BLASTX using
BLOSUM62 scoring matrix and a word size of 3, to protein
sequences of TAIR 10 representative gene models (Arabidop
sis.org on the WorldWideWeb) with an E-value limit of 1 e-5.
The top hit(s) for each query sequence was retained based on
best bit score and E-value. Secondly TAIR 10 models (above)
were matched to assembly elements (isotigs and singletons)
using tBLASTN with an E-value limit of 1 e-5. Candidate
acyl lipid metabolism gene sequences were retrieved from
BLAST result sets above were trimmed to include only these
genes. The best isotig for each isogroup was retained, trim
ming outputative alternative transcripts of the same gene (as
described in Nguyen et al., 2013, Plant Biotechnol. J., 11(6),
759-769.

Example 9
Isolation of Multiple Putative LPAT Paralogs in
Cuphea Species
0103) To isolate specialized LPAT for medium chain acyl
CoA, we performed the RNA sequencing and assembly of
over 2 million 454 sequencing pyrosequencing reads from the
developing seeds of C. pulcherrima (recently re-classified as
C. avigera var. pulcherrima) and C. viscosissima. Nucleotide
sequence similarity to Arabidopsis LPAT2 was used for iden
tification of potential LPAT orthologs. Six full-lengths of
LPAT candidate genes were isolated in the 454 sequencing
transcriptome of C. pulcherrima, and one full-length of LPAT
candidate gene was found in the 454 sequencing transcrip
tome of C. viscosissima. We used the 7 full-lengths of putative
LPAT genes for further studies.
0104. The evolutionary relationship of cuphea LPAT
genes was investigated based on their deduced amino acid
sequences to collect more information about relationships
and to predict function for TAG accumulation. The sequences
were aligned with putative orthologs of higher plants, which
were described by Manas-Fernandez et al. (2013, Europ. J.
Lipid Sci. Technol. 115:1334-6) and Arroyo-Caro et al.
(2013, Plant Sci., 199:29-40), and obtained the sequences
from the protein database of the National Center for Biotech
nology Information (NCBI). LPATs have been sub-grouped
by plastid LPAT (LPAT1) and microsomal LPAT, and then the

latter was further categorized into two classes, A and B. The
class A microsomal LPATs are typical enzymes involved in
synthesis of membrane glycerolipids, they show ubiquitous
expression in plants and have a substrate preference for 18:1CoA. Based on the category of Arabidopsis LPATs, the class
A microsomal LPATs were further divided into 2 subgroups
as LPAT2/LPAT3 group and LPAT4/LPAT5 group. The class
B microsomal LPAT (LPATB) is classified as a seed-specific
isoform and is found in plants accumulating unusual fatty
acids in their seed oil. Even though LPATB is a microsomal
LPAT, the class has a closer relationship with plastidal LPAT1
than other plant groups. However, LPATB is closer to the
enzyme of other organisms, such as E. coli, yeast, and human.
0105 Four genes of class A LPAT, one gene of LPATB,
and one gene of LPAT1 were found in C. pulcherrima. Based
on the classification, these LPATs were named as CpuLPAT1,
CpuLPAT2a, CpulPAT2b. CpuLPAT2c, CpuLPAT3 and
CpulPATB (FIG. 1). One LPAT gene from C. viscosissima
was isolated, classified as class A, and named as CVLPAT2

(FIG. 1). CpuLPATB belonged to the same group as Cn LPAT,
which was isolated in coconut and related to increase of lauric

acid by incorporating this fatty acid into the Sn-2 position of
TAG in transgenic plants seeds (Knutzon, et al., 1999, Plant
Physiol. 109:999-1006). Based on the relationship between
coconut LPATB and MCFA, we assumed that CpuLPATB
might involve the increase of MCFA in TAG. So the studies
were focused to reveal the function of CpulPATB. Because
CVLPAT2 was the only LPAT gene isolated from C. viscosis
sima, the functional studies of CvLPAT2 were performed in
parallel.
Example 10
Acyltransferase Motifs and Topology of
Transmembrane Domain in Cuphea LPATs
010.6 An amino acid alignment reveals a high level of
amino acid identity among plant LPATBs (FIG. 2A). The
LPLAT-AGPAT-like domain of CpuLPATB shared 82%,
79%, 77%, 74% and 70% identities with Vitis vinifera (XP
002278280), Ricinus communis AFR42414, Oryza sativa
(CAH66825), Cocos nucifera Q42670, and Limnanthes
douglasii Q42870, respectively. The domain showed a low
identity with other organisms such as 40% (Homo sapiens,
NP006402), 39% (Homo sapiens, NP006403), 36% (Saccha
romyces cerevisiae, SLC1, P33333), and 34% (Escherichia
coli, PlsC, AAA24397). We predicted that there were 4 con
served acyltransferase motifs in CpulPATB, which are
NH(X). D (motif I, residues 137-143), GHLRIDR (motif II,
residues 178-183), FPEGTR (motif III, residues 210-215),
and LPIVPIVL (motif IV, residues 237-244) (FIG. 7A).
These are significantly important on acyltransferase activi
ties. Hydrophobic motif II was first characterized as an acyl
CoA-binding site in animal cells and might modulate acyl
CoA selectivity and residue “EGT in motif III has been
presumed to be involved in the binding of the LPA.
0107 To predict transmembrane domain sequences, struc
tural analysis of the gene model-translated protein sequences
was carried out in silico using SOSUI bp.nuap.nagoya-u.ac.
jp/sosui?on the World Wide Web, PSORTII psort.hgc.jp/
form2.html on the World WideWeb, HMMTOP enzim.hu/
hmmtop?on the World WideWeb, and TMHMM server 2.0
cbs.dtu.dk/services/TMHMM/ on the World WideWeb. All
programs predicted only one transmembrane domain in
CpulPATB in a similar region (FIG.7B). Based on the analy
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sis of motif and transmembrane domain, the predicted topol
ogy of CpuLPATB was presented in FIG. 7C, where all acyl
transferase motifs were on the cytosolic side of the ER
membrane.

0108. The deduced amino acid sequence alignment of
CvLPAT2 with CpuLPAT2a, CpuLPAT2b CpuLPAT2c, and
CpulPAT3 showed the amino acid identities as 82%, 79%,
79% and 66%, respectively, in full amino acid sequences, and
87%, 79%, 79% and 66%, respectively, in LPLAT-AGPAT
like domain. The amino acid identity between CpulPAT2b
and CpuLPAT2c was the highest at 97% in LPLAT-AGPAT
like domain. The key motifs in LPLAT-AGPAT-like domains
were conserved well among the LPAT2s in diverse plant
species (FIG. 8A). As for Motif I NH(X), D and motif III
(FPEGTR), the same sequences with LPATTB, were
observed in CVLPAT2 and in LPAT2/3 group from C. pull
cherrima. Motif II (LPVLGW) and motif IV (NVLIPRT
KGFV) were conserved in plant LPAT2/3 group, but those
sequences were completely different with the LPATB's.
There was a putative tyrosine phosphate site in motif VRCX)
Y(X). A from CvLPAT2 like the other LPAT2/3 group.
Transmembrane domain of CVLAAPT2 was predicted as dif
ferent numbers by different programs; 4 by SOSUI, 3 by
PSORTII and HMMTOP and 5 by TMHMM (FIG. 8B). All
programs predicted the N-terminal located in cytosol and
C-terminal located in the ER lumen. Therefore, we predicted
that there are five transmembrane domains in CvLPAT2 as

seen in caster bean and presented the predicted topology of
CVLPAT2 in FIG. 8C, where motif I is located in cytosol and
motif II-IV is located in the ER lumen by separating the third
transmembrane domain.

Example 11
Tissue-Specific Expression of Cuphea LPAT

copy of tapetum cells and by immunoblotting of Subcellular
fraction. We investigated the subcellular localization of
CpuLPAT2a, CpuLPATB, and CvLPAT2 by using a laser
scanning confocal microscope. Yellow fluorescence protein
(YFP) was fused with C-terminal of eachLPAT driven by 35S
promoter. Each pro35S:LPAT:YFP was transiently co-ex
pressed with the ER-rk CD3-959 as the ER marker (FIG.
3A-C) in tobacco leaves by agro-infiltration method. YFP
signals of CpuLPAT2a, CpuLPATB, and CvLPAT2 were
detected as the reticular shape and co-localized with ER
marker. The result demonstrated that CpulPAT2a, Cpull
PATB, and CvLPAT2 are microsomal LPAT localized in the

ER. We also tested the subcellular localization of CpuLPAT1,
which is classified as a plastidal form. YFP signal of Cpull
PAT1 was detected in the out membrane of chloroplasts (FIG.
3D).
Example 13
CpulPATB Complemented the E. coli Mutant,
JC2O1

0111. To test the activities of Cuphea. LPATs, a comple
mentation test was performed in an E. coli JC201 mutant,
which is a temperature-sensitive mutant of plsC and able to
grow at 30°C., but not at 42°C. The full-length open reading
frames of Cuphea LPATs were cloned into the pEBluescript
SK vector. FIG. 4A showed that all Cuphea LPATs and an
empty vector grew at 30° C. Occasionally the JC201 cells
with an empty vector grew at 42°C., and we increased the
incubation temperature as 44° C. Only JC201 containing
CpulPATB was able to grow at 44°C., but few colonies were
observed in the JC201 containing other LPATs (FIG. 4A). To
confirm the result, we tested their growth rate by measuring
the ODconcentration in process of time. As seen in FIG. 4B,

Isoforms

the cell concentration of JC201 increased in all tested

0109 Different LPAT isoforms showed the various
expression patterns and levels in the diverse tissues of a plant.
Because LPAT has been considered a narrow substrate speci
ficity, tissue specific expression is one of the clues to presume
their function. RT-PCR was performed using cDNAs from
diverse tissues, such as roots, stems, leaves, flowers and
developing seeds, to investigate the tissue specificity and the
expression level of LPAT genes in C. pulcherrima and C.
viscosissima (FIG. 2). The transcripts of CpulPAT1 were
abundant in all tested tissues except developing seeds.
CpulPAT2b and CpuPAT3 showed ubiquitous expression
patterns with a low expression levels. CpulPAT2c was unde
tectable at the same PCR cycle numbers as other LPAT genes,
however, when PCR cycle numbers were increased it was
slightly detected in all tissues tested. Interestingly,
CpulPAT2a and CVLPAT2, which have very high sequence
similarity (82% in amino acid), showed the developing seed
specific expressions. CpuPATB was also exclusively
detected in the developing seeds. These results indicate that
CpuLPATB, CpuLPAT2a and Cv PAT2 might be involved in
the accumulation of MCFAs at the sn-2 position of TAG.
Example 12

CpuLPATB and CvLPAT2 Preferentially
Incorporated 14:0 and 10:0, Respectively, into the

CpuLPATB, CpuLPAT2a, and CvLPAT2 Localize in
the ER

0110. The ER localization of LPAT2 was confirmed in
Arabidopsis and Brasicca by immunofluorescence micros

Cuphea. LPATs and empty vector control at 30°C. However,
only CpulPATB showed the increase of OD concentration at
44° C. We tested the LPAT activity in the inducible vector,
pET-duet, but the results were the same as above, even in the
presence or absence of IPTG, Only CpulPATB comple
mented the E. coli mutant JC201 a LPAT activity. This result
was correlated with the amino acid homology of LPATs
between plant and E. coli. CpulPATB shares the most similar
homology with E. coli LPAT (34% in domain).
Example 14
Sn-2 Position of TAG

0112 To investigate the activities of Cuphea LPATs in
planta and its utility for oilseed metabolic engineering, the
CpulPATB and CVLPAT2 genes were introduced into Cam
elina along with the variant FatB thioesterase genes. CpFatB2
is 14:0 specific thioesterase of Cuphea palustris (Dehesh et
al., 1996, Plant Physiol. 110:203-10) and ChFatB2 is 8:0 and
10:0 specific FatB thioesterase of Cuphea hookeriana (De
hesh et al., 1996, The Plant J., 9:167-72). The seed-specific
glycinin promoter was used to drive the CpuLPATB and the
seed-specific oleosin promoter was used to drive the CVL
PAT2 for exclusive gene expression in seed. Lauric acid
specific CnLPAT was used for a comparison with CpulPATB
and CVLPAT2. The expression of CpFatB2 in Camelina
showed 26.3 mol % of 14:0 fatty acid. When Cpfath32 was
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co-experessed with CnLPAT, CpuLPATB or CvLPAT2, the
levels of 14:0 fatty acid were further increased as 33.1 mol%.
36.5 mol % or 32.9 mol %, respectively. The expression of
ChFatB2 in Camelina showed 7.4 mol % of 10:0 fatty acid.
Co-expression of ChFatB2 with CnLPAT or CvLPAT2
increased the 10:0 fatty acid as 10.2 mol % or 11.8 mol %,
respectively. However, CpuLPATB didn't increase the 10:0
fatty acid with ChFatB2 (FIG. 5). The positional distribution
of the MCFA was also determined in TAG. Trace amounts of

16:0 and 18:0 were detected at the sn-2 position of TAG in
wild type. The composition of MCFA at the sn-2 position of
TAG was 2.9 mol% (14:0) and 1.1 mol% (16:0) in Cpfath32
Camelina seeds. Myristic acid the sn-2 position of TAG from
CpFatB2 Camelina seeds was significantly increased up to
14.2 mol% with CnLPAT, 19.7 mol % with CpuLPATB, and
14.8 mol % with CvLPAT2 (FIG. 5B). The sn-2 position of
TAG in ChFatB2 was not occupied by any MCFA or saturated
fatty acid. Co-expression of ChFatB2 with CvLPAT2 resulted
in the significant increase of 10:0 (15.4 mol %) at the sn-2
position of TAG. However, 10:0 fatty acid was barely
detected in the coexpression line of ChFatB2 and Cn PAT.
CpuLPATB didn't effect on the increase of 10:0 fatty acid
with ChFatB2 in the transgenic Camelina seeds. These results
indicate that CpuLPATB and CVLPAT2 enhance the accumu
lation of the saturated MCFAs in the TAG of Camelina seed

by incorporating medium chain acyl-CoA into the Sn-2 posi
tion of LPA. CpulPATB has a preference toward 14:0 fatty
acid and CVLPAT2 has a preference toward myristic acid and
capric acid.
Example 15
The Distribution of MCFA in TAG Molecular

Species
0113 To further investigate the metabolism of MCFA in
transgenic Camelina seeds, we performed ESI-MS analysis
for the molecular species of TAG from Camelina producing
the FatBTE. Absolute peak intensity of mass spectra of TAG
species from seeds expressing the FatBTE and LPAT were
presented in FIG. 6 and FIG. 10. TAG species with at least one
14:0 represent in plants expressing Cpfath32 with CnLPAT,
CpuLPATB, and CvLPAT2, respectively, while any MCFA
was not detected in the TAG in wild-type Camelina (FIG. 6).
The levels of tri-MCFA-TAG species increased when
CpFatB2 expressed with LPATs and the highest amount tri
MCFA-TAG species was observed in CvLPAT2. Tri-MCFA
TAG species in transgenic Camelina seeds confirmed that
tested LPATs contain the preference to saturated MCFAs and
CVLPAT2 is the best FatBTE for those Substrates.
Part B

Example 16
Cloning Cpl DGAT1 Sequence from C. pulcherrima
0114. The Cpl DGAT1 gene sequence was identified in the
C. pulcherrima 454 sequence data generated as described
before (Nguyen et al., 2013, Plant Biotechnol.J., 11:759-69).
The ORF designated as Cpl DGAT1 of 1482 bp encoding 484
amino acids was PCR amplified from C. pulcherrima cDNA
using the gene specific primers.
0115 For expression in yeast the native version of Cpl D
GAT1 ORF was amplified using the primer pair
CpDGAT1BamHIf and CplDGAT1Xbair. The ORFs for N

terminus truncated and mutated versions were generated
using the forward primers Cpl DGAT1 trunc BamHI and
CpDGAT1AlaBamHIf, respectively. The ORF for the trun
cated version (Cp)GAT1 trunc) of Cpl DGAT1 is 70 amino
acids shorter at N terminus than the native version. The align
ment showed that the 70 amino acid N terminus of Cpl DGAT1
is unique and is different from that of other DGAT1s while the
amino acid sequence downstream the 70 amino acids is
highly similar to that of DGAT1s from A. thaliana, O. euro
pea, B. napus and O. sativa. The length of the differing N
terminus region of the DGAT1s from different plant species

varies. In the mutated version the CAT coding for His was

replaced by GAG coding for Ala in the forward primer,
CpGAT1 AlaBamHIf. Thus three constructs pYes2 Cpl D
GAT1, pYes2 CplDGAT1Ala, and pYes2 CpDGAT1 trunc
were made for expression in yeast.
0116 For generating plant transformation vectors the
ORF encoding for Cpl DGAT1 and CpGAT1 trunc were sub
cloned into NotI sites of pKMS3 vector generating Glycinin
promoter and terminator containing CpGAT1 gene cassette.
The cassette was subsequently released by AscI to be cloned
into Mlul site of plBinClyRed3+CvFatB1 yielding pBinG
lyRed3 CvFatB1+CpDGAT1 or pBinGlyRed3 CvFatB1+
CpGAT1 trunc. The backbone of the vector is derived from
pCAMBIA0380 and was engineered with the DSRed marker
gene under the control of the constitutively-expressed cassava
mosaic virus promoter for selection of transgenic seeds by
fluorescence (Lu and Kang, 2008, Plant Cell Rep. 27:273-8).
Similarly, A. thaliana DGAT1 was subcloned into the binary
vector generating pBinGlyRed3 CvPat31+Athl)GAT1 for
transformation into Camelina.

Example 17
Phylogenetic Analysis
0117. An unrooted phylogenetic tree of Cpl DGAT1
deduced amino acid sequence along with other amino acid
sequences homologous to DGAT1 or DGAT2 including sev
eral functionally characterized ones was constructed. The
functional and phylogenetic relationships were identified by
the neighbor joining program in MEGA4 (Tamura et al.,
2007, Mol. Biol. Evol., 24:1596-9). The bootstrap analysis
was performed with 1,000 replicates.
Example 18
Yeast Transformation and Selection

0118. The constructs pYes2 CplDGAT1, pYes2
CpGAT1 Ala, and pYes2 Cpl DGAT1 trunc were trans
formed into S. cerevisiae strain H1246 (W303; MATC. are 1
A: HIS3 are2-A::LEU2dga1:KanMX4 lro1-A::TRP1 ADE2
met ura3) (Sandager et al., 2002, J. Biol. Chem..., 277:6478
82) using PEG/lithium acetate method (Gietz et al., 1995,
Yeast, 11:355-60). The yeast cells harboring the empty pYes2
vector were used as negative control. Transformants were
selected by uracil prototrophy on yeast synthetic medium
(YSM) containing 2% (w/v) glucose and lacking uracil (Invit
rogen, Carlsbad, Calif. USA). For functional expressionYSM
containing 2% (w/v) raffinose was inoculated with the yeast
transformants and grown at 28°C. for 24h in a shaker at 350
rpm. For induction, YSM containing 2% (w/v) galactose was
inoculated with raffinose-grown cultures to obtain an OD of
0.2 at 600 nm and grown at 28°C. for 48 h. For fatty acid
feeding experiments cultures were grown for 2.5 hs in YSM
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containing 2% galactose followed by addition of 1% (w/v)
Tergitol-40 and 250 uM of the appropriate fatty acid sub
strate. Cells were harvested by centrifugation, washed twice
with 0.1% NaHCO3, freeze-dried and used for fatty acid,
TAG analysis and microsome isolation.
Example 19
Camelina Transformation and Selection

0119 The binary vector containing a cassette for seed
specific expression of Cpl DGAT1, Cpl DGAT1 trunc or Athl)GAT1 was introduced into Agrobacterium tumefaciens by
electroporation. Transgenic plants were generated by floral
dip of Camelina wt plants (Lu and Kang, 2008, Plant Cell
Reports, 27:273-8). Transgenic seeds among mature seeds
were selected using DsRed marker and were also PCR con
firmed. Expression of transgenes in developing seeds was
confirmed by RT-PCR.
Example 20
TAG Quantification and FA Profiling
0120 Total lipid extraction by Bligh Dyer: 30 mg of Cam
elina seeds was weighed in glass test tubes, followed by
addition of 270 ul (10 mg/ml) C17-TAG and 50 ul (1 mg/ml)
C17-PC. Seeds were crushed in 3 ml methanol: chloroform

(2:1 v/v) by grinding with a grinder and incubated for 1 h at
room temperature with agitation. Extraction was continued
by adding 1 ml of chloroform and 1.9 ml of water to a test tube
and vortexed, centrifuged at 4000 rpm for 10 minutes. The
organic (lower) phase was transferred to a new test tube, 400
ul was saved for transesterification. The rest was used for
separation of TAG, DAG and Polar lipids using Supelco Supel
Clean LC-Si SPE (Sigma) columns. Dried total lipids were
redissolved in 1 ml of heptane and loaded onto LC-Si SPE
columns equilibrated according to manufacturer's guide
lines, once the sample ran through the column first wax esters
were eluted with 1.5 ml of 95:5 heptane: ethyl ether, second
TAG fraction was eluted with 5 ml of heptane: ethyl ether
80:20 (v/v). DAG was eluted with 3 ml chloroform: acetone
80:20 (v/v). Columns were washed with 6 ml of acetone
followed by elution of phospholipids with 5 ml methanol:
chloroform: water 100:50:40 (v/v/v). Total phospholipids
were pooled with addition of 1.33 ml chloroform and 1.31 ml
water followed by vortexing and centrifugation at 4000 rpm
for 10 minutes. The organic phase containing total phospho
lipids was transferred into a new tube.
0121 600 ul of polar lipid fraction was dried and transes
terified the rest was redessolved in 100 ul chloroform and
separated by TLC in a solvent system consisting of CHCl3:
MeOH:H2O:30% ammonium hydroxide (65:35:3:2.5 V/v/v/
v). Bands from the TLC plates corresponding to PC were
scraped onto wax paper and transferred to 13x100 mm test
tubes. Transesterification of total lipids, TAG, and phospho
lipid fractions was done in 1 ml of 2% sulphuric acid in
methanol by heating at 90° C. for 30 min. Upon cooling the
samples to room temperature 1 ml HO and 1 ml heptane was
added followed by Vortexing and centrifuging. Heptane layer
was transferred to GC vials and analyzed in GC..
Example 21
Isolation of C. pulcherrima DGAT1 and DGAT2
Genes

0122 Potential genes identified as DGATs were blasted
against A. thaliana gene database in TAIR BLAST 2.2.8. The

blast identified one gene model highly similar to A. thaliana
DGAT1 thus named Cpl DGAT1. In addition three genes two
of which are similar to R. communis, V. fordii DGAT2 were
identified and designated as CpGAT2 A and Cpl DGAT2 C,
the third one is similar to A. thaliana DGAT2 and was named

CpDGAT2 B. The ORF of CpDGAT1 is 1482 bp encoding a
484 amino acid polypeptide (Altschul et al., 1997, Nucl.
Acids Res., 25:3389-402). Homology search blast analysis of
484 deduced amino acid showed it being most identical, 59
and 54%, to functionally characterized DGAT1s from A.
thaliana and B. napus, respectively, while it shares ~39%
identity with mammalian DGAT1S (FIG.11). The N terminus
78 amino acids has no sequence homology in other known
homologous DGAT1S (FIG. 12), the hydrophilic N-terminus
of 151 and 80 residues in plants and animals, respectively,
were found to be unique for every DGAT1. Nevertheless, the
rest is highly conserved and identical to DGAT1s from plant
species such as A. thaliana, B. napus, R. communis and O.
sativa (FIG. 12). The SOSUI secondary structure prediction
program predicted ten transmembrane regions in CpGAT1.
Similarly 8-10 hydrophobic regions were identified in
DGAT1s of different origins (Liu et al., 2012, Plant Biotech
nol. J., 10:862-70). The average number of residues is higher
for DGAT1s than that of DGAT2s corresponding to 20 kDa
difference in molecular mass. Expression of Cpl DGAT1 in
H1246 mutant, which contains disruptions of four acyltrans
ferase genes that contribute to TAG synthesis, did not store
TAG biosynthesis to the S. cerevisiae while Athl)GAT1
expressing H1246 yeast cells make TAG. Expression of
codon optimized CpGAT1 in H1246 yeast cells did not lead
to any differences. Similarly, DGAT assay using radiola
belled 10:0 and DAG 10:0/10:0 Substrates with microsomes

from CpGAT1 expressing yeast cells did not result in for
mation of TAG.

Example 22
Tissue-Specific Expression of C. pulcherrima
DGATS

(0123 Expression profile of CpDGAT1, CpDGAT2 A,
CpGAT2 B and Cpl DGAT2 C in root, stem, leaf, flower
and developing seeds of C. pulcherrima was analyzed (FIG.
13). The transcript abundance of the genes was normalized to
that of C. pulcherrima eukaryotic initiation factor and actin
(CpelF4 and Cp Actin) genes. It was found that Cpl DGAT1 is
specifically expressed in developing seeds. The three C. pull
cherrima DGAT2 genes expression was observed in all tis
sues, stronger expression of CpGAT2 A, Cpl DGAT2 B can
be seen in developing seeds while Cpl DGAT2 C is expressed
at similar levels in all tissues analyzed.
Example 23
Seed-Specific Expression of Cpl DGAT1 and
CVLPAT2 Enhances Decanoic Acid and Caprylic
Acid Content in Camelina sativa Seeds

0.124 Cpl DGAT1 was expressed under seed specific gly
cinin-1 promoter along with the C. viscosissima thioesterase
(CvFatB1), known to be specific for C10:0, C12:0, C14:0 and
C16:0 Acyl-ACP CvLPAT2 the ORF of 1155 bp was ampli
fied from a cDNA prepared from total RNA from C. visco
sissima from developing seeds. It was cloned into pBinG
lyred vector under glycinin-1 promoter.
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0.125 Analysis of seeds from T2 plants of 24 independent
lines expressing CvFatB1+Cpl DGAT1 and CvPat31+CVL
PAT2+Cpl DGAT1, as confirmed by reverse-transcription
PCR, showed increased amounts of 10:0 (FIGS. 14 and 15).
The 10:0 fatty acid levels in transgenic CvFatB1+CpGAT1
and CvFatB1+CvLPAT2+CpDGAT1 T2 seeds reached as
high as 13.5 and 21.5 mol% of TFA as compared to 8.0 mol
% in lines expressing only CvFatB1, while that of C12:0.
C14:0 and C16:0 stayed similar (FIGS. 14 and 15). Signifi
cant decrease in the amounts of 18:2, 18:3 and 20:1 by 10, 18
and 6 mol %, respectively, was seen in all CvFatB1+Cp)GAT1 transgenic lines. The oil content in seeds from T3
homozygous transgenic lines from CvFatB1+Cpl DGAT1
(FIG. 14) and CvFatB1+CvLPAT2+CplDGAT1 (FIG. 15),
which had the highest amounts of 10:0, was not significantly
affected. In addition to C10:0, 3 to 5 mol % of C8:0 was

detected in TAG in the seeds engineered to express CvFatB1+
CvLPAT2+CplDGAT1.
Example 24
Enhanced Amounts of C8:0 and C10:0 are Detected

at Sn-2 Position of TAG from Seeds of Transgenic
Camelina Lines Expressing CvLPAT2 or/and
CplDGAT1
0126 Stereospecific analysis of fatty acid species at sn-2
position of TAG from engineered seeds was conducted to
assess the efficiency of assembly of short and medium chain
fatty acids in TAG. Fatty acid profile of sn-2 monoacylglyc
erol obtained by digesting with TAG sn-1 and sn-3 specific
lipase from Rhizomucor miehei (Sigma) revealed that while
trace amounts of 10:0 is seen at sn-2 position of TAG from
seeds of CvFatB1+CpGAT1 lines, there is a striking
increase up to 20 mol% in CvFatB1+CvLPAT2 line and 33.1
mol % in the relative content of 10:0 at Sn-2 of TAG from

CvFatB1+CvLPAT2+CpDGAT1 line was observed (FIG.
17). In addition to C10:0, 3 to 5 mol% of C8:0 was detected
in TAG sn-2 position in the seeds engineered to express
CvFatB1+CvLPAT2+CplDGAT1.
0127. The increase of 10:0 at the sn-2 position of TAG
from CvFatB1 expressing lines is accompanied by reduction
of 18:2 and significantly that of 18:3 which is 17.4 mol % as
compared to 44.3 mol % at this position in TAG from Wt
camelina seeds. In C. pulcherrima fatty acid species at Sn-2
position of TAG are 8:0 (up to 97 mol%) and C10:0 (3 mol%)
while in C. viscosissima it is 12.6 mol% of C8:0 and 87.4 mol

% of 10:0 (FIG. 17).
Example 25
DAG Species from C. sativa Transgenic Lines
Overexpressing Cuphea Species Acyltransferases
Contain Increased Amounts of Shorter Chain

Saturated Fatty Acids
0128 Fatty acid profile of DAG species from the trans
genic lines was analyzed (FIG. 18). The data showed higher
amounts of C10:0 and C16:0 fatty acids in lines expressing
the Cuphea acyltransferases CVIPAT2 and Cpl DGAT1 in
addition to the thioesterase, CvFatB1. The seeds of CvFatB1

expressing lines contain ~4 mol % of C10:0, ~12 mol % of
C16:0, while that of CvFatB1+CpDGAT1 and CvFatB1+
CvLPAT2 contain up to 8 mol% of C10:0, 3 mol% of C14:0
and 20 mol % of C16:0. DAG species from CvFatB1+CvL
PAT2+Cpl DGAT1 contain highest amount of C10:0 up to 14

mol%. The increase in the amounts of short and medium

chain fatty acids in DAG species is accompanied by Substan
tial decrease of 18:3. DAGs from developing seeds of C.
viscosissima contain up to 12, 53, 8 and 32 mol % of C8:0,
C10:0, C14:0 and C16:0, respectively.
Example 26
Accumulation of Short- and Medium-Chain Fatty
Acids in Transgenic Camelina Lines Starts at
Midstage in Developing Seeds
I0129. Fatty acid composition of developing seeds from
transgenic Camelina lines were analyzed at four stages after
flowering: 10 DAF, 17 DAF, 22DAF and 30 DAF. Ten day
developing seeds contain very low 10:0 (-2.5 mol %), main
fatty acids are 16:0 (-14 mol %), 18:1 (20 mol %), 18:2
(40-44 mol%), and 18:3 (18-20 mol%), the predominant one.
The percent share of each fatty acid (C16:0 through 20:1) in
TFA in transgenic lines is similar to that of wild type Cam
elina plants. 17 day seeds produce more of shorter chain fatty
acids 8:0 (4 mol %), 10:0 (up to 24 mol %), 12:0 (2.5-4 mol
%), 14:0 (3 mol%) and higher amounts of 16:0 (13 mol%) in
transgenic lines. In CvPat31+CvLpat2+Cpl DGAT1 the
amount of 18:1 decreases, while 18:2, 18:3 and 20:1 make 15

mol %, 16 mol % and 6 mol %, respectively, as compared to
21.4, 30 and 12.7 mol % in wild type Camelina plants.
0.130 22 day seeds produce more of short chain fatty acids
5 mol % C8:0, 30 mol % 10:0, 7 mol % (12:0-14:0). The
amounts of 16:0, 18:0, 18:1, 18:2, 18:3 and 20:1 in CvEatB1+
CvLPAT2+CpDGAT1 line are 12, 8, 12, 16, and 5 mol % as
compared to 8, 13, 20, 41, and 10 mol% in seeds of wild type
plants. Thus the share of 8:0 through 16:0 fatty acids total
amount in this line reaches 54 mol % of TFA as compared to
39 mol% in CvFatB1 line, 43% in CvFatB1+CpDGAT1 line
and 8 mol % in wild type.
I0131. In 30 days in seeds from CvFatB1 line there is 33.6
mol % of 8:0-16:0, 22.4 mol%. 18:1, 13.7 mol%. 18:2, 16.0

mol% 18:3 and 6.6 mol%20:1. CvFatB1+CpDGAT1 trans
genic lines accumulate more 10:0, and 8:0-10:0 total fatty
acids amount is 37.5 mol% while amounts of 18:1, 18:2, 18:3
and 20:1 are similar to what is found in seeds from CvFatB1

line. In CvFatB1+CvLPAT2+CpDGAT1 line the average
share of 8:0-16:0 fatty acids is 43 mol% of TFA, 18.5 mol%
being 10:0 and 13.2 mol % 18:1, 12.8 mol%. 18:2, 18.3 mol
% 18:3, 6.3 mol%20:1.

0.132. As seeds develop oil content increases in both wild
type and transgenic Camelina lines. Major oil accumulation
started in 17 days at which oil content doubled 26.5% as
compared to 13% of dry weight in 10 days, followed by
33.4% and 28%, after 22 and 30 days, respectively, in wild
type. In CvFatB1+CVLPAT2+Cpl DGAT1 lines average oil
content was 13%, 26%, 30% and 22.7%, as compared to
thioesterase only expressing lines 11.8, 23.0, 24.6, and
23.4%, in 10, 17, 22 and 30 days, respectively.
Example 27
CpDGAT1 has Preference for 10:0 Containing
Substrates and Decanoyl CoA
I0133) Substrate preferences of CpDGAT1 were tested
using extracts from 22 day developing seeds of CvEATB1.
CvFatB1+CpDGAT1, and CvFatB1+CvLPAT2+CpDGAT1
(FIG. 20). Acyl-CoA dependent DGAT activity was exam

ined by measuring the incorporation of ''C acyl-CoA into
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DAG acceptors 10:0/10:0 (1,2-didecanoyl-sn-glycerol) or
18:1/18:1 (1,2-dioleoyl-sn-glycerol). In seed extracts of
CpGAT1 expressing lines TAG formation from 1,2-DAG
10:0/10:0 and 10:0-CoA was enhanced. DGAT activity with
1,2-DAG 10:0/10:0 and 10:0-CoA was similar 80.6+4.1 and
63.6+23.4 pmol TAG/min/g protein in Wt and CvPat31
expressing line, respectively. In CvPat31+Cpl DGAT1 and
CvFatB1+CvLPAT2+CpDGAT1 lines the activity was
346+77.5 and 323+57.9 pmol TAG/min/g protein, respec
tively.
Example 28
Germination Efficiency of Short- and Medium-Chain
Fatty Acid Rich Transgenic Camelina Seeds
0134 High levels of short and medium chain fatty acids
did not affect average seed weight observed for transgenic
seeds obtained in greenhouse conditions (FIG. 20). The
weight of 100 seeds from wild type Camelina was 79 mg, 74
mg for CvFatB1,71 and 77 mg for CvFatB1+CpDGAT1, and
CvFatB1+CvLPAT2+CpDGAT1 lines, respectively.
0135 Germination efficiency of homozygous 10:0-16:0
rich transgenic Camelina seeds was not significantly affected
by high levels of 10:0 or increased amounts of 16:0 (FIG.22).
Up to 93% of seeds from CvFatB1 line germinated in 10 days
in greenhouse conditions, for CvFatB1+CpDGAT1 it was
78% and 97% for CvFatB1+CvLPAT2+CplDGAT1, which
contains highest amounts of short and medium chain fatty
acids.

Example 29
Seed-Specific Expression of Cpl DGAT1 and
CvLPAT2a Further Enhances Decanoic Acid Content
in Camelina sativa Seeds

(CvFatB1), known to be specific for C8:0 and C10:0 Acyl
ACP. The CpuPAT2a ORF of 1164 bp was amplified from
cDNA prepared from total RNA from C. pulcherrima devel
oping seeds and was sub-cloned into pKMS3 vector under
glycinin-1 promoters. A cassette comprising the glycinin-1
promoter and CpulPAT2a gene was inserted into the pBinG
lyRed-CvFatB1+CpDGAT1 to make the pBinGlyRed-Cv
FatB1+CpuLPAT2a+CpDGAT1.
0.137 Analysis of seeds from T2 lines expressing
CvFatB1+CvLPAT2+CpDGAT1 and T3 lines expressing
CvFatB1+CpuLPAT2a+CpDGAT1 showed increased
amounts of 10:0 in TAG (FIGS. 16 and 24). The 10:0 fatty
acid levels in transgenic CvFatB1+CvLPAT2a+CpGAT1
T3 seeds reached as high as 18.5 and 27 mol% of TAGTFA
as compared to 8.0 mol% in lines expressing only CVPat31,
while that of C18:1, C18:2 and C18:3 stayed similar (FIGS.
16 and 24). The oil content in seeds from T3 transgenic lines
from CvFatB1+CvLPAT2a+CpDGAT1 (7,11), which had
high amounts of 10:0, was not significantly affected (FIG.
24A). The amount of C10:0 is even higher in seeds of Cam
elina lines expressing CpulPAT2a in addition to CvFatB1
and CpGAT1 (CvFatB1+CpulPAT2a+CpDGAT1). Fatty
acid profile of Sn-2 monoacylglycerol obtained by digesting
with TAG sn-1 and sn-3 specific lipase from Rhizomucor
miehei (Sigma) indicated a significant increase in 10:0 at Sn-2
position of TAG from seeds of both CvFatB1+CvLPAT2+
CplDGAT1 (FIG. 17) and CvFatB1+CpuLPAT2a+CplDGAT1
(FIG. 24B) lines. It is notable also that 8:0 was detected in
amounts of ~3 mol % in the total TAG and in the TAG sn-2

0.136 Cpl DGAT1 was expressed under seed specific gly
cinin-1 promoter along with the C. viscosissima thioesterase

position in seeds engineered to express CvFatB1+
CvLPAT2CpuLPAT2a+CplDGAT1.
TABLE 1.

Primers used for cloning CpDGAT1 and AthlGAT1 into yeast and
Camelina expression vectors
C. pulcherrima primers used for expression in yeast and
Camelina

CpDGAT1BamHIf

CTAGGATCCAccATGgctCATGAGGCAGTCAG HisBamHI

CpDGAT1AlaBamHIf

CTAGGATCCAccATGgctCAGGCAGTCAGC

BamHI

CpDgat1trunc BamH1f GTCGGATCCAccATGGCTCACCGGACTTCA

BamHI

CpDGAT1Xballr

ATATCTAGACTAGTCGATCCTTAATCCTC

Xbar

CpDGlnot1F

ATAgcggcc.gcATGCATGAGGCAGTCAG

BamH1

TABLE 2

Primers used for SQRT-PCR of Cp)GAT1, Cpl.)GAT2 A, Cp)GAT2 B,
and CpGAT2 C
Primer sequence 5'-3'

Amplicon

Gene name

Primer name

Forward Reverse

size (bp)

Cpl.)GAT1

SQCpDG1f
SQCpDG1r
Cpl DGsqf
Cpl DGsqr
CPDG2 2 sqF
CPDG2 2 sqR

CTTCAATCTCTGTATGGTCACTCTC
GACATCAAGGCACAATCAAATCTC
GGAGATTCGCGAGGAGCTTAAGTAGG,
CATATGGAATGTCTCCTGCACACCAC
GAGCGAGATGCTGAGATTGTGTTCCT.
TCACTGTGCACCTCATTCACCTCTTC

298

CpDG2 3hinsa F

TGGTGTGCAGGAGACATTCTACATGGf

381

Cpl.)GAT2 A
Cpl.)GAT2 B

Cpl.)GAT2 C

ACTTGTGCCTTGTGTCGCTCGAATAG

347
3O8
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TABLE 2-continued
Primers used for SQRT-PCR of Cpl.)GAT1, Cp)GAT2 A, Cpl.)GAT2 B,
and CDDGAT2 C
Primer sequence 5'-3'

Amplicon

Gene name

Primer name

Forward Reverse

size (bp)

Cp Actin

CpACTf
CpACTr

TTGCTTTGGACTACGAGCAGGAGAf
TGGAGTTGTAAGTCGTCTCGTGGA

189

CpeIF4 RT F

GGTGAAGCGTGACGAACTGAC

140

CpeIF4 RT R

|CTCTAGTGTTCTGGTCCATGTCTCC

CeIF4

Cp)g1trF Not1
CpDg1R Not1

ATAgcggcc.gcATGGCTCACCGGACTTCA

Not

AATGCGGCCGCCTAGTCGATCCTTAAT

Not

Primers used for expression of CpDGAT2 genes in yeast
Cpdg1

CTAGGATCCAccATGCGGGAGGAGACGAA

BamHI

Cpdg2

atatotagaTCAAAGGATTCTCAGTTTGA

Xba

Cpdg3

CTAGGATCCAccATGATAGGGTTCalATGA

BamHI

Cpdg4

atatotagaTCACAAAATTCTCAGTTCGA

Xba

Cpdg5

citaAAGCTTAccATGGGAGAGGAGGCGGAC

HindIII

Cpdgó

atacticgagTTAAAGTATTCTCAGTTTGA

XhoI

A. thaliana DGAT1 primers used for cloning into yeast and Camelina transformation
AthBanDGAT1F
AthlxbaDGAT1R

CTAGGATCCAccATGGCGATTTTGGATTC
ATATCTAGATCATGACATCGATCCTTTTC

BamHI
Xba

AthlNotif

ATAgcggcc.gcATGGCGATTTTGGATT

Notf

Athnotr

SEA

Notr

0138. It is to be understood that, while the methods and
compositions of matter have been described herein in con
junction with a number of different aspects, the foregoing
description of the various aspects is intended to illustrate and
not limit the Scope of the methods and compositions of matter.
Other aspects, advantages, and modifications are within the
Scope of the following claims.
0139 Disclosed are methods and compositions that can be
used for, can be used in conjunction with, can be used in
preparation for, or are products of the disclosed methods and
compositions. These and other materials are disclosed herein,
and it is understood that combinations, Subsets, interactions,

groups, etc. of these methods and compositions are disclosed.
That is, while specific reference to each various individual
and collective combinations and permutations of these com
positions and methods may not be explicitly disclosed, each is
specifically contemplated and described herein. For example,
if a particular composition of matter or a particular method is
disclosed and discussed and a number of compositions or
methods are discussed, each and every combination and per
mutation of the compositions and the methods are specifically
contemplated unless specifically indicated to the contrary.
Likewise, any Subset or combination of these is also specifi
cally contemplated and disclosed.

SEQUENCE LISTING
<16 Os NUMBER OF SEO ID NOS : 16
<21 Os SEQ ID NO 1
&211s LENGTH: 1155
&212s. TYPE: DNA

<213> ORGANISM: Cuphea viscosissima
<4 OOs SEQUENCE: 1

atgg.cgattg cagoggcago tdtcatcttic ct citt.cggcc titat cittctt cqcctic cqgc

60

ct cattatca at citct tcca gg.cgctittgc tittgtcc tta titcqgc citct tt cqaaaaac

12O

gcc taccgga gaataalacag agtttittgca gaattgttgt titcggagct tt tatgccta

18O

titcgattggit gggctggtgc taagctcaaa ttatttaccg accctgaaac ctitt cqccitt

24 O

atgggcaagg aa catgctct ggit cataatt aat cacatga ctgaacttga Ctggatggitt

3 OO

ggatgggitta tiggit cagca ttittggttgc Cttgggagca taat atctgt togaagaaa

360

tdaacaaaat ttct tcc.ggit attggggtgg to aatgtggit titt cagagta cctatat citt

42O

gagagaa.gct gggccaagga taaaagtaca ttaaagt cac at atcgagag gCtgatagac

48O

taccc cctdc ccttctggitt gg taatttitt gtggaaggaa ct cqgtttac toggacaaaa

54 O
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Ctcttggcag cccagcagta totgtct catctgggctac Cagtgcc.gag aaatgttittg

6OO

atcc cacgta ctaagggittt tdttt catgt gtgagt caca togcgat catt togttc.ca.gca

660

gtatatgatgtcacagtggc attcc ctaag actt cacctic caccaacgtt gctaaatctt

72 O

titcgagggtc agt ccataat gct tcatgtt cacat caagc gacatgcaat gaaagattta

78O

ccagaatc.cg atgatgcagt agcagagtgg ttagagaca aatttgttgga aaaggatgct

84 O

ttgttggaca agcataatgc tigaggacact ttcagtggtc. aagaagttctg. t cataccggc

9 OO

agcc.gc.cagt taaagttct ct tctggtggta at at Cttggg tttgtaac alacatttggg

96.O

gctictaaagt t cctt Cagtg gtcat catgg aaggggaaag catttitcagc tat cqggctg

1 O2O

ggcatcgt.ca citc tactitat gcacg tattg attctat cot cacaa.gcaga gcggit coaac

108 O

Cctg.cggagg tecac aggc aaa.gctaaag accgggttgt Catctgaaa galaggtaacg

114 O

gacaaggaaa act ag

1155

<210s, SEQ ID NO 2
&211s LENGTH: 384
212. TYPE: PRT

<213> ORGANISM: Cuphea viscosissima
<4 OOs, SEQUENCE: 2

Met Ala Ile Ala Ala Ala Ala Val Ile Phe Lieu. Phe Gly Lieu. Ile Phe
1.

5

1O

15

Phe Ala Ser Gly Lieu. Ile Ile Asn Lieu. Phe Glin Ala Lieu. Cys Phe Val
2O

25

3O

Lieu. Ile Arg Pro Lieu. Ser Lys Asn Ala Tyr Arg Arg Ile Asin Arg Val
35

4O

45

Phe Ala Glu Lieu Lleu Lleu Ser Glu Lieu. Lieu. Cys Lieu. Phe Asp Trp Trp
SO

55

6O

Ala Gly Ala Lys Lieu Lys Lieu. Phe Thr Asp Pro Glu Thir Phe Arg Lieu
65

70

7s

8O

Met Gly Lys Glu. His Ala Lieu Val Ile Ile Asn His Met Thr Glu Lieu.
85

90

95

Asp Trp Met Val Gly Trp Val Met Gly Gln His Phe Gly Cys Lieu. Gly
1OO

105

11 O

Ser Ile Ile Ser Val Ala Lys Llys Ser Thr Llys Phe Lieu Pro Val Lieu.
115

12 O

125

Gly Trp Ser Met Trp Phe Ser Glu Tyr Lieu. Tyr Lieu. Glu Arg Ser Trp
13 O

135

14 O

Ala Lys Asp Llys Ser Thr Lieu Lys Ser His Ile Glu Arg Lieu. Ile Asp
145

150

155

160

Tyr Pro Leu Pro Phe Trp Leu Val Ile Phe Val Glu Gly Thr Arg Phe
1.65

17O

17s

Thir Arg Thr Lys Lieu. Lieu Ala Ala Glin Glin Tyr Ala Val Ser Ser Gly
18O

185

19 O

Lieu Pro Val Pro Arg Asn Val Lieu. Ile Pro Arg Thr Lys Gly Phe Val
195

2OO

2O5

Ser Cys Val Ser His Met Arg Ser Phe Val Pro Ala Val Tyr Asp Val
21 O

215

22O

Thr Val Ala Phe Pro Llys Thr Ser Pro Pro Pro Thr Lieu. Lieu. Asn Lieu.
225

23 O

235

24 O
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Phe Glu Gly Glin Ser Ile Met Lieu. His Val His Ile Lys Arg His Ala
245

250

255

Met Lys Asp Lieu Pro Glu Ser Asp Asp Ala Val Ala Glu Trp Cys Arg
26 O

265

27 O

Asp Llys Phe Val Glu Lys Asp Ala Lieu. Lieu. Asp Llys His Asn Ala Glu
27s

28O

285

Asp Thr Phe Ser Gly Glin Glu Val Arg His Thr Gly Ser Arg Glin Leu
29 O

295

3 OO

Lys Ser Lieu. Leu Val Val Ile Ser Trp Val Val Val Thr Thr Phe Gly
3. OS

310

315

32O

Ala Lieu Lys Phe Lieu Gln Trp Ser Ser Trip Lys Gly Lys Ala Phe Ser
3.25

330

335

Ala Ile Gly Lieu. Gly Ile Val Thir Lieu. Lieu Met His Val Lieu. Ile Lieu
34 O

345

35. O

Ser Ser Glin Ala Glu Arg Ser Asn Pro Ala Glu Val Ala Glin Ala Lys
355

360

365

Lieu Lys Thr Gly Lieu. Ser Ile Ser Lys Llys Val Thr Asp Llys Glu Asn
37 O

375

38O

<210s, SEQ ID NO 3
&211s LENGTH: 1164
&212s. TYPE: DNA

<213> ORGANISM: Cuphea avigera var. pulcherrima
< 4 OO

SEQUENCE: 3

atgacgattig catcggcago tdtcgt.ctitt ctdtt cqgca ttct c ct citt cacct coggc

6O

ct cattatca atctottcca gg.cgttittgc tictdtcc titg tittggcct ct titcgaagaac

12 O

gcct accqiga gaattaac cq agtttittgca gaatttittgc ccttggagtt tittatggcta

18O

titccattggt giggctggtgc taagctcaaa ttatttaccg accctgaaac ctitt.cgc citt

24 O

atgggcaagg alacatgct ct tt cataatt aat cacalaga ttgagcttga Ctggatggitt

3OO

ggatgggttctgggtcagca tttaggttgc Cttgggagca tattatc.cgt togalagaaa

360

t caacaaaat ttctt.ccggit ttittgggtgg to attatggit titt cagagta t ct attt citt

42O

gagagaaact gggccalagga taaaaaaa.ca ttaaagt cac atatagagag gctgaaagat

48O

tacic ccct gc cct tctggitt gataatttitt gtggaaggaa citcggitttac toggacaaaa

54 O

Ctcttggcag cccagcagta totgcctica gctgggttac Cagtgcc.gag aaatgttittg

6OO

atcc cacata ctaagggittt tdttt catct gtgagt caca togcgat catt togttc.cggca

660

atatacgatgtcacggtggc attcc ctaag acttic acctic caccaacgat gctaaaactt

72 O

titcgagggtc attic.cgtaga gct tcacgtt Cacat Caagc ggcatgcaat gaaagattta

78O

ccagaatc.cg aagatgcagt agcacagtgg ttagagaca aatttgttga gaaggatgct

84 O

ttgttggaca agcataatgc tigaggacact ttcagtggtc. aagaagttca t catgtcggc

9 OO

cgc.ccgataa agt ctottct ggtggtaata t cqtgggtgg ttgtaataat atttggggct

96.O

ctaaagttcc titcagtgg to at cact citta t catcatgga aggggaaagc attitt cagtt

1 O2O

atcgggttgg gcactgtc.gc act act catg caaat attga ttctatoctic acaag cagag

108 O

cggit ct at CC Ctgccaagga gacaccggca aatctaaaga ccgagttgtc. gtcCtcaaag

114 O

alaggtaacga acaaggaaaa ctag

1164.
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<210s, SEQ ID NO 4
&211s LENGTH: 387
212. TYPE: PRT

<213> ORGANISM: Cuphea avigera var. pulcherrima
<4 OOs, SEQUENCE: 4

Met Thr Ile Ala Ser Ala Ala Val Val Phe Leu Phe Gly Ile Leu Lieu.
1.

5

1O

15

Phe Thir Ser Gly Lieu. Ile Ile Asn Lieu Phe Glin Ala Phe Cys Ser Val
2O

25

3O

Lieu Val Trp Pro Lieu. Ser Lys Asn Ala Tyr Arg Arg Ile Asin Arg Val
35

4O

45

Phe Ala Glu Phe Lieu Pro Leu Glu Phe Leu Trp Leu Phe His Trp Trp
SO

55

6O

Ala Gly Ala Lys Lieu Lys Lieu. Phe Thr Asp Pro Glu Thir Phe Arg Lieu
65

70

7s

8O

Met Gly Lys Glu. His Ala Lieu Val Ile Ile Asn His Lys Ile Glu Lieu.
85

90

95

Asp Trp Met Val Gly Trp Val Lieu. Gly Glin His Lieu. Gly Cys Lieu. Gly
1OO

105

11 O

Ser Ile Leu Ser Val Ala Lys Llys Ser Thr Llys Phe Leu Pro Val Phe
115

12 O

125

Gly Trp Ser Leu Trp Phe Ser Glu Tyr Lieu. Phe Lieu. Glu Arg Asn Trp
13 O

135

14 O

Ala Lys Asp Llys Llys Thr Lieu Lys Ser His Ile Glu Arg Lieu Lys Asp
145

150

155

160

Tyr Pro Leu Pro Phe Trp Lieu. Ile Ile Phe Val Glu Gly Thr Arg Phe
1.65

17O

17s

Thir Arg Thr Lys Lieu. Lieu Ala Ala Glin Glin Tyr Ala Ala Ser Ala Gly
18O

185

19 O

Lieu Pro Val Pro Arg Asn Val Lieu. Ile Pro His Thr Lys Gly Phe Val
195

2OO

2O5

Ser Ser Val Ser His Met Arg Ser Phe Val Pro Ala Ile Tyr Asp Val
21 O

215

22O

Thr Val Ala Phe Pro Llys Thr Ser Pro Pro Pro Thr Met Leu Lys Lieu.
225

23 O

235

24 O

Phe Glu Gly. His Ser Val Glu Lieu. His Val His Ile Lys Arg His Ala
245

250

255

Met Lys Asp Lieu Pro Glu Ser Glu Asp Ala Val Ala Glin Trp Cys Arg
26 O

265

27 O

Asp Llys Phe Val Glu Lys Asp Ala Lieu. Lieu. Asp Llys His Asn Ala Glu
27s

28O

285

Asp Thr Phe Ser Gly Glin Glu Val His His Val Gly Arg Pro Ile Llys
29 O

295

3 OO

Ser Lieu. Leu Val Val Ile Ser Trp Val Val Val Ile Ile Phe Gly Ala
3. OS

310

315

32O

Lieu Lys Phe Lieu. Glin Trp Ser Ser Lieu. Lieu. Ser Ser Trp Llys Gly Lys
3.25

330

335

Ala Phe Ser Val Ile Gly Lieu. Gly. Thr Val Ala Lieu Lleu Met Glin Ile
34 O

345

35. O

Lieu. Ile Lieu. Ser Ser Glin Ala Glu Arg Ser Ile Pro Ala Lys Glu Thir
355

360

365
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115

12 O

125

Asn Glu Arg Ala Ile Tyr Ile Cys Asn His Ala Ser Pro Lieu. Asp Ile
13 O

135

14 O

Val Lieu. Thir Met Trp Lieu. Thr Pro Lys Gly Thr Val Cys Ile Ala Lys
145

150

155

160

Lys Glu Ile Val Trp Tyr Pro Lieu. Ile Gly Glin Lieu. Tyr Ala Lieu Ala
1.65

17O

17s

Gly His Lieu. Arg Ile Asp Arg Ser Asn Pro Val Ala Ala Ile Glin Ser
18O

185

19 O

Met Lys Glu Val Ala Arg Ala Val Val Lys Asn Asp Lieu. Ser Lieu. Ile
195

2OO

2O5

Ile Phe Pro Glu Gly Thr Arg Ser Lys Asp Gly Arg Lieu. Lieu Pro Phe
21 O

215

22O

Llys Lys Gly Phe Val His Lieu Ala Lieu. Glin Thr Arg Arg Pro Ile Val
225

23 O

235

24 O

Pro Ile Val Lieu. Thr Gly Thr His Met Ala Trp Arg Lys Gly Ser Lieu.
245

250

255

His Ile Arg Pro Thr Pro Leu. Thr Val Lys Tyr Lieu Pro Pro Ile Val
26 O

265

27 O

Thir Thr Asp Trp Thr Pro Asp Arg Val Glu Asp Tyr Thr Lys Met Ile
27s

28O

285

His Asp Ile Tyr Val Asn His Lieu Pro Glu Ser Glin Gln Pro Lieu. Arg
29 O

295

3 OO

Pro Lys Glu Ser
3. OS

<210s, SEQ ID NO 7
&211s LENGTH: 1482
&212s. TYPE: DNA

<213> ORGANISM: Cuphea avigera var. pulcherrima
<4 OO > SEQUENCE: 7
atgcatgagg cagt cago catttitcticcac cqccacgc.cc cactic totct citc.cggcttic

6O

gccatgg.cga t cqtcagogg cactic toggc gtc.gcagcct cotcc tt cat ccc.cgacticc

12 O

gat cacticca ccacct ct co ttct citcc.gc aagcdcaact cotct tcact ttitt.cccaag

18O

gcct cagaca cittcttctgt cqacggcaag gocgct cacc ggactitcatc. tcc.ggttcac

24 O

ttgaaactgg cagagagt cc tict cagotcg agaaat atct tcaag cagala t catgaaggt

3OO

citct tcaatc. tctgtatggit cact citcgtt gctgtcatca toccact citt cotcgagaat

360

CtcCtcaagt atggttggct aatgaagaga gacttittggit tagtacgtt Cacagcctgg

42O

cc.gct citt catttgtagcct cqgtc.ttic cc attitt coccc ttgcago att cqtagt cdag

48O

aagttggc cc agaagaatct tctg.ccggaa ccgattgttt tatgttctica tdt cattatc

54 O

actitcggcat cogtcc titta t ccc.gcactt gtaattctga gatttgattg togccttgatg

6OO

tctggitat cq gtctgatgct c tatt cittgc gct ctittggit taaaattggit gtc.ctatgcg

660

Cacacaagtt acgatatgag atgtgaggcc aagttct catc ttgagggaala aagtagtgcg

72 O

gattcaaaaa atggagagct tcc ttaccgc gtaaa.catca aagat cittgc gtact tcatg

78O

gttgcaccga ccctatgtta cca.gctitt cq tat cotcgca cacaattitat acgtaaattit

84 O

tgggtggctic gccaagttctt gaagttgata ttggt caatig tagtaatggg attcatCatt

9 OO
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gaacaatata tatt ccc.gt tatgcataac totaaac ccc cacggcgggg at attggitta

96.O

cattt catcg agagaaattt gaagcttgcg gttcCaagta taggcctgtg gttittgcata

O2O

ttct actic catttitt catct ctdgctgaat at agtggcgg agctic ct cog titttgg.cgat

O8O

cgtgaattitt ataaagattg gtggaatgcc aagaatatgg aggagtact.g. galagatgtgg

14 O

alacatacctg. t t cataggtg gatggttcga catttatacg gtcCttgcat galagagaaaa

2OO

ttac.cgaggt giggit cqcg at ttctatot catttct cittgt ctdcagtgtt gcatgagat c

26 O

tgtgtaagtg titc catgc.ca ttgttcCag Ctttgggcat t caacggaat gatgctt cag

32O

attic.cgctgg tttgagttc gaalaccctta caaaagaggit toccaagctic taaggctggg

38O

aatgtatt ct tctggttctt gttttgtatic tatggc.cago ctaattgttgt gct tatgtac

44 O

taccacgc.ct tatggaacg gagaggatta aggat.cgact ag

482

<210s, SEQ ID NO 8
&211s LENGTH: 493
212. TYPE: PRT

<213> ORGANISM: Cuphea avigera var. pulcherrima
<4 OOs, SEQUENCE: 8

Met His Glu Ala Val Ser His Phe Lieu. His Arg His Ala Pro Leu Ser
1.

5

1O

15

Lieu. Ser Gly Phe Ala Met Ala Ile Val Ser Gly Thr Lieu. Gly Val Ala
2O

25

3O

Ala Ser Ser Phe Ile Pro Asp Ser Asp His Ser Thr Thr Ser Pro Ser
35

4O

45

Lieu. Arg Lys Arg Asn. Ser Ser Ser Lieu. Phe Pro Lys Ala Ser Asp Thr
SO

55

6O

Ser Ser Val Asp Gly Lys Ala Ala His Arg Thir Ser Ser Pro Val His
65

70

7s

8O

Lieu Lys Lieu Ala Glu Ser Pro Lieu. Ser Ser Arg Asn. Ile Phe Lys Glin
85

90

95

Asn His Glu Gly Lieu. Phe Asn Lieu. Cys Met Val Thir Lieu Val Ala Val
1OO

105

11 O

Ile Ile Arg Lieu. Phe Lieu. Glu Asn Lieu. Lieu Lys Tyr Gly Trp Lieu Met
115

12 O

125

Lys Arg Asp Phe Trp Leu Ser Thr Phe Thr Ala Trp Pro Leu Phe Ile
13 O

135

14 O

Cys Ser Leu Gly Lieu Pro Ile Phe Pro Leu Ala Ala Phe Val Val Glu
145

150

155

160

Llys Lieu Ala Glin Lys Asn Lieu. Lieu Pro Glu Pro Ile Val Lieu. Cys Ser
1.65

17O

17s

His Val Ile Ile Thr Ser Ala Ser Val Lieu. Tyr Pro Ala Leu Val Ile
18O

185

19 O

Lieu. Arg Phe Asp Cys Ala Lieu Met Ser Gly Ile Gly Lieu Met Lieu. Tyr
195

2OO

2O5

Ser Cys Ala Leu Trp Leu Lys Lieu Val Ser Tyr Ala His Thr Ser Tyr
21 O

215

22O

Asp Met Arg Cys Glu Ala Lys Ser Arg Lieu. Glu Gly Llys Ser Ser Ala
225

23 O

235

24 O

Asp Ser Lys Asn Gly Glu Lieu Pro Tyr Arg Val Asn. Ile Lys Asp Lieu
245

250

255
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Ala Tyr Phe Met Val Ala Pro Thr Lieu. Cys Tyr Gln Leu Ser Tyr Pro
26 O

265

27 O

Arg Thr Glin Phe Ile Arg Llys Phe Trp Val Ala Arg Glin Val Lieu Lys
27s

28O

285

Lieu. Ile Leu Val Asn Val Val Met Gly Phe Ile Ile Glu Glin Tyr Met
29 O

295

3 OO

Ile Pro Val Met His Asn Ser Llys Pro Pro Arg Arg Gly Tyr Trp Leu
3. OS

310

315

32O

His Phe Ile Glu Arg Asn Lieu Lys Lieu Ala Val Pro Ser Ile Gly Lieu.
3.25

330

335

Trp Phe Cys Ile Phe Tyr Ser Ile Phe His Leu Trp Lieu. Asn Ile Val
34 O

345

35. O

Ala Glu Lieu. Lieu. Arg Phe Gly Asp Arg Glu Phe Tyr Lys Asp Trp Trip
355

360

365

Asn Ala Lys Asn Met Glu Glu Tyr Trp Llys Met Trp Asn. Ile Pro Val
37 O

375

38O

His Arg Trp Met Val Arg His Lieu. Tyr Gly Pro Cys Met Lys Arg Llys
385

390

395

4 OO

Lieu Pro Arg Trp Val Ala Ile Ser Ile Ser Phe Lieu Lleu Ser Ala Val
4 OS

41O

415

Lieu. His Glu Ile Cys Val Ser Val Pro Cys His Val Phe Glin Leu Trp
42O

425

43 O

Ala Phe ASn Gly Met Met Lieu. Glin Ile Pro Leu Val Lieu Ser Ser Lys
435

44 O

445

Pro Leu Gln Lys Arg Phe Pro Ser Ser Lys Ala Gly Asn Val Phe Phe
450

45.5

460

Trp Phe Leu Phe Cys Ile Tyr Gly Glin Pro Asn Cys Val Leu Met Tyr
465

470

47s

48O

Tyr His Ala Lieu Met Glu Arg Arg Gly Lieu. Arg Ile Asp
485

490

<210s, SEQ ID NO 9
&211s LENGTH: 1419
&212s. TYPE: DNA

<213> ORGANISM: Cuphea viscosissima
<4 OOs, SEQUENCE: 9

atggcgat.cg ttggcgt.cga cqctt cotcc ct cagtc.ccg act ct ct cog cc.ggcgcaac

6O

titcgaccalag Ctt cactict c ticc calagacic accggcggca gtgttgtcga tigacgctgat

12 O

aacttgaagc tiggagcgcga cqC caagaaa got caccgga Ctt Catct cc ggtacactgg

18O

aagttggctg agagtic ct ct cagct coacc aatat citt.ca agcagagtica togcaggit ct c

24 O

ttaa acct cit gcatggtcgt tottattgct gtcaa.ca.gcc gact catcct cqagaat ct c

3OO

atcaagtatg gttggct cat galagaggaac ttittggttgc atacgtttac agactggcct

360

citct tcatgt gtagcc ttgg tott.cccatt titc cct cittg cagcatt cot agt cdagaag

42O

ttggcgcago ggaatcgttt gcc tdaacct attgt attitt gttct catgt cattat cact

48O

acggcatc.cg toctittatcc cqc acttgta attctgggat citgattctgc cittgat citct

54 O

gg tattgttctgatgct cat togcttgcact ctittggittaa aattggtgtc. atatgcgcac

6OO

acaagttacg atatgagatg taggccaag tict Cttcttg aggga caatic tagtgctgct

660

tcaaaaaatg tagagcttico ttaccg.cgta aacttcaaag atc.ttgttgta titt catggitt

72 O
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gcacccaccc tatgttacca gattt coitat cotcgcacac aatgtgtacg taaaggttgg

78O

gttgct cqcg aagttcttgaa gttgatattgttcaatggag taatgggatt cat cattgaa

84 O

caatatatga titcctic titat gcatalactict aaaggcc cac agaggggaga ttggitta cat

9 OO

ttcatcgaaa gogattittgaa gottgcggitt coaggcgitat acctgtggitt ttgcatatt c

96.O

tactgcattt ttcatctotg gttgaatata citggcagagc ticcitatgttt tdgcgatcqt

1 O2O

gaattittata gagactggtg gaatgccaag alacatggagg agtactggala gatgtggaac

108 O

atacctgttc ataagtggat ggtgcggc at ttatacggtc. cct gcttgaa gaggaaaata

114 O

cc.gagg togg togcaatttic tat ct cattt citcttgtctg cagtgttgca tdagct tatt

12 OO

gtcagtatt c catgccatgt gttcatgctg tdggcattca citggaatgat actitcagatt

126 O

cc.gctggttt tagttctgaa accCttacaa aaaatgttcc agagctc.cgt ggctgggaat

132O

atgttcttct ggttcttctt ttgcatctitt ggc.ca.gc.cca totgttgtgct tatgtactac

1380

Catgcc atga tiggat.cgtaa aatat cacag accgactag

1419

<210s, SEQ ID NO 10
&211s LENGTH: 472
212. TYPE: PRT

<213> ORGANISM: Cuphea viscosissima
<4 OOs, SEQUENCE: 10

Met Ala Ile Val Gly Val Asp Ala Ser Ser Lieu Ser Pro Asp Ser Lieu
1.

5

1O

15

Arg Arg Arg Asn. Phe Asp Glin Ala Ser Lieu. Ser Pro Llys Thir Thr Gly
2O

25

3O

Gly Ser Val Val Asp Asp Ala Asp Asn Lieu Lys Lieu. Glu Arg Asp Ala
35

4O

45

Llys Lys Ala His Arg Thr Ser Ser Pro Wal His Trp Llys Lieu Ala Glu
SO

55

6O

Ser Pro Leu Ser Ser Thr Asn Ile Phe Lys Glin Ser His Ala Gly Lieu.
65

70

7s

8O

Lieu. Asn Lieu. Cys Met Val Val Lieu. Ile Ala Val Asn. Ser Arg Lieu. Ile
85

90

95

Lieu. Glu Asn Lieu. Ile Llys Tyr Gly Trp Lieu Met Lys Arg Asn. Phe Trp
1OO

105

11 O

Lieu. His Thr Phe Thr Asp Trp Pro Leu Phe Met Cys Ser Leu Gly Lieu.
115

12 O

125

Pro Ile Phe Pro Lieu Ala Ala Phe Lieu Val Glu Lys Lieu Ala Glin Arg
13 O

135

14 O

Asn Arg Lieu Pro Glu Pro Ile Val Phe Cys Ser His Val Ile Ile Thr
145

150

155

160

Thir Ala Ser Val Lieu. Tyr Pro Ala Lieu Val Ile Lieu. Gly Ser Asp Ser
1.65

17O

17s

Ala Lieu. Ile Ser Gly Ile Val Lieu Met Lieu. Ile Ala Cys Thr Lieu. Trip
18O

185

19 O

Lieu Lys Lieu Val Ser Tyr Ala His Thir Ser Tyr Asp Met Arg Cys Glu
195

2OO

2O5

Ala Lys Ser Lieu. Lieu. Glu Gly Glin Ser Ser Ala Ala Ser Lys Asn Val
21 O

215

22O

Glu Lieu Pro Tyr Arg Val Asn Phe Lys Asp Leu Val Tyr Phe Met Val
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225

23 O

235

24 O

Ala Pro Thr Lieu. Cys Tyr Glin Ile Ser Tyr Pro Arg Thr Glin Cys Val
245

250

255

Arg Lys Gly Trp Val Ala Arg Glu Val Lieu Lys Lieu. Ile Lieu. Phe Asn
26 O

265

27 O

Gly Val Met Gly Phe Ile Ile Glu Gln Tyr Met Ile Pro Leu Met His
27s

28O

285

Asn Ser Lys Gly Pro Glin Arg Gly Asp Trp Lieu. His Phe Ile Glu Arg
29 O

295

3 OO

Ile Leu Lys Lieu Ala Val Pro Gly Val Tyr Lieu. Trp Phe Cys Ile Phe
3. OS

310

315

32O

Tyr Cys Ile Phe His Lieu. Trp Lieu. Asn. Ile Lieu Ala Glu Lieu. Lieu. Cys
3.25

330

335

Phe Gly Asp Arg Glu Phe Tyr Arg Asp Trp Trp Asn Ala Lys Asn Met
34 O

345

35. O

Glu Glu Tyr Trp Llys Met Trp Asn Ile Pro Val His Lys Trp Met Val
355

360

365

Arg His Lieu. Tyr Gly Pro Cys Lieu Lys Arg Lys Ile Pro Arg Ser Val
37 O

375

38O

Ala Ile Ser Ile Ser Phe Lieu. Lieu. Ser Ala Val Lieu. His Glu Lieu. Ile
385

390

395

4 OO

Val Ser Ile Pro Cys His Val Phe Met Leu Trp Ala Phe Thr Gly Met
405

410

415

Ile Lieu. Glin Ile Pro Lieu Val Lieu. Ser Ser Llys Pro Lieu Gln Lys Met
42O

425

43 O

Phe Glin Ser Ser Val Ala Gly Asn Met Phe Phe Trp Phe Phe Phe Cys
435

44 O

445

Ile Phe Gly Glin Pro Met Cys Val Lieu Met Tyr Tyr His Ala Met Met
450

45.5

460

Asp Arg Lys Ile Ser Glin Thr Asp
465

470

<210s, SEQ ID NO 11
&211s LENGTH: 126 O
&212s. TYPE: DNA

<213> ORGANISM: Cuphea viscosissima
<4 OOs, SEQUENCE: 11
atggtggctg ctgcagdaac ttctgcattc titcc.ccgttc cagc.cccggg aacct cocct

6O

aaac ccggga agt ccggcaa citggc catcg agcttgagcc ctaccttcaa gcc caagttca

12 O

atc.cccaatg gcggattt Caggitta aggca aatgc.ca.gtg cc catcc tala ggctaacggit

18O

tctgcagtaa atctaaagtic toggcagocto aac acticagg aggacacttic gtcgt.ccc.ct

24 O

cctic ccc.ggg ctitt cottaa ccagttgcct gattggagta togcttctgac togcaat cacg

3OO

accgt.ctt.cg tdgcggcaga galagcagtgg accatgcttgataggaaatc taagaggcct

360

gacatgctic

tigact cqgt tigttgaag agt attgttc gagatgggct cqtgtcCaga

42O

cacagtttitt cqattagatc titatgaaata gg.cgctgatc gaacago: ct c tatagagacg

48O

citgatgaacc acttgcagga aacaactato aat cattgta agagtttggg tott cataat

54 O

gacggCtttg gtcgtact co togatgtgt aaaaacgacc ticatttgggit gct tacaaaa

6OO

atgcagat.ca tdtgaatcg ct accCaact toggtgata ctgttgagat Caatacctgg

660
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ttct ct cagt cqgggaaaat cqg tatggct agcgattggc taataagtga ttgcaacaca

72 O

ggagaaattic titataagagc aacgagcgtg tdggctatga tigaatcaaaa gacgagalaga

78O

ttct caagac titc catacga gottcgc.cag gagittaacac ct cattttgt gigact ct cot

84 O

Catgtcattg aagacaatga t cagalaattig cqtaagtttg atgtgaagac tdgtgatt CC

9 OO

attcgcaagg gtctaact co gaggtggaat gaCttggatg taat cagca cqtaa.gcaac

96.O

gtgaagtaca ttgggtggat t ct cagagt atgcc-aatag aagttittgga gacccaggag

1 O2O

Ctatgct Ctc. tcaccgttga atataggcgg gaatgcggala tigacagtgt gctggagt cc

108 O

gtgactgctg tdgatcCctic agaaaatgga ggc.cggit ct c agtacaa.gca cct tctg.cgg

114 O

Cttgaggatg ggactgat at C9tgaagagt agaactgagt ggcgaccgala gaatgcagga

12 OO

actaacgggg catat caac at Caacagca aagacittcaa atggaaactic ggt ct ct tag

126 O

<210s, SEQ ID NO 12
&211s LENGTH: 419
212. TYPE: PRT

<213> ORGANISM: Cuphea viscosissima
<4 OOs, SEQUENCE: 12
Met Wall Ala Ala Ala Ala Thir Ser Ala Phe Phe Pro Wall Pro Ala Pro
1.

5

1O

15

Gly. Thir Ser Pro Llys Pro Gly Lys Ser Gly Asn Trp Pro Ser Ser Lieu.
2O

25

30

Ser Pro Thr Phe Llys Pro Llys Ser Ile Pro Asn Gly Gly Phe Glin Val
35

4O

45

Lys Ala Asn Ala Ser Ala His Pro Lys Ala Asn Gly Ser Ala Val Asn
SO

55

6O

Lieu Lys Ser Gly Ser Lieu. Asn Thr Glin Glu Asp Thr Ser Ser Ser Pro
65

70

7s

8O

Pro Pro Arg Ala Phe Lieu. Asn Glin Lieu Pro Asp Trp Ser Met Lieu. Lieu.
85

90

95

Thr Ala Ile Thr Thr Val Phe Val Ala Ala Glu Lys Gln Trp Thr Met
1OO

105

11 O

Lieu. Asp Arg Llys Ser Lys Arg Pro Asp Met Lieu Val Asp Ser Val Gly
115

12 O

125

Lieu Lys Ser Ile Val Arg Asp Gly Lieu Val Ser Arg His Ser Phe Ser
13 O

135

14 O

Ile Arg Ser Tyr Glu Ile Gly Ala Asp Arg Thr Ala Ser Ile Glu Thr
145

150

155

160

Lieu Met Asn His Lieu. Glin Glu Thir Thr Ile Asn His Cys Llys Ser Lieu.
1.65

17O

17s

Gly Lieu. His Asn Asp Gly Phe Gly Arg Thr Pro Gly Met Cys Lys Asn
18O

185

19 O

Asp Lieu. Ile Trp Val Lieu. Thir Lys Met Glin Ile Met Val Asn Arg Tyr
195

2OO

2O5

Pro Thir Trp Gly Asp Thr Val Glu Ile Asn. Thir Trp Phe Ser Glin Ser
21 O

215

22O

Gly Lys Ile Gly Met Ala Ser Asp Trp Lieu. Ile Ser Asp Cys Asn. Thir
225

23 O

235

24 O

Gly Glu Ile Lieu. Ile Arg Ala Thir Ser Val Trp Ala Met Met Asn Glin
245

250

255
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gctatggat.c cct caaaagt tagt cc.gt tot cagtacc agc acct tct gcggcttgag

114 O

gatgggactg. Ctatcgtgaa cigtgcaact gagtggcggc cqaagaatgc aggagctaac

12 OO

gggg.cgat at Caacgggaaa gacttcaaat ggaaact cqg tct Cttag

1248

<210s, SEQ ID NO 14
&211s LENGTH: 415
212. TYPE: PRT

<213> ORGANISM: Cuphea hookeriana
<4 OOs, SEQUENCE: 14
Met Wall Ala Ala Ala Ala Ser Ser Ala Phe Phe Pro Wall Pro Ala Pro
1.

5

1O

15

Gly Ala Ser Pro Llys Pro Gly Llys Phe Gly Asn Trp Pro Ser Ser Lieu.
2O

25

3O

Ser Pro Ser Phe Llys Pro Llys Ser Ile Pro Asn Gly Gly Phe Glin Val
35

4O

45

Lys Ala Asn Asp Ser Ala His Pro Lys Ala Asn Gly Ser Ala Val Ser
SO

55

6O

Lieu Lys Ser Gly Ser Lieu. Asn Thr Glin Glu Asp Thr Ser Ser Ser Pro
65

70

7s

8O

Pro Pro Arg Thr Phe Lieu. His Glin Lieu Pro Asp Trp Ser Arg Lieu. Lieu.
85

90

95

Thr Ala Ile Thir Thr Val Phe Val Llys Ser Lys Arg Pro Asp Met His
1OO

105

11 O

Asp Arg Llys Ser Lys Arg Pro Asp Met Lieu Val Asp Ser Phe Gly Lieu
115

12 O

125

Glu Ser Thr Val Glin Asp Gly Lieu Val Phe Arg Glin Ser Phe Ser Ile
13 O

135

14 O

Arg Ser Tyr Glu Ile Gly Thr Asp Arg Thr Ala Ser Ile Glu Thir Lieu
145

150

155

160

Met Asn His Leu Gln Glu Thir Ser Lieu. Asn His Cys Lys Ser Thr Gly
1.65

17O

17s

Ile Lieu. Lieu. Asp Gly Phe Gly Arg Thr Lieu. Glu Met Cys Lys Arg Asp
18O

185

19 O

Lieu. Ile Trp Val Val Ile Llys Met Glin Ile Llys Val Asn Arg Tyr Pro
195

2OO

2O5

Ala Trp Gly Asp Thr Val Glu Ile Asn. Thir Arg Phe Ser Arg Lieu. Gly
21 O

215

22O

Lys Ile Gly Met Gly Arg Asp Trp Lieu. Ile Ser Asp Cys Asn Thr Gly
225

23 O

235

24 O

Glu Ile Lieu Val Arg Ala Thir Ser Ala Tyr Ala Met Met Asin Gln Lys
245

250

255

Thir Arg Arg Lieu. Ser Llys Lieu Pro Tyr Glu Val His Glin Glu Ile Val
26 O

265

27 O

Pro Lieu. Phe Val Asp Ser Pro Val Ile Glu Asp Ser Asp Lieu Lys Val
27s

28O

285

His Llys Phe Llys Val Llys Thr Gly Asp Ser Ile Glin Lys Gly Lieu. Thir
29 O

295

3 OO

Pro Gly Trp Asn Asp Lieu. Asp Wall Asn Gln His Val Ser Asn. Wall Lys
3. OS

310

315

32O

Tyr Ile Gly Trp Ile Lieu. Glu Ser Met Pro Thr Glu Val Lieu. Glu Thr
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1.

5

1O

15

Val Thr Ser Ser Arg Pro Gly Llys Pro Gly Asn Gly Ser Ser Ser Phe
2O

25

3O

Ser Pro Ile Llys Pro Llys Phe Val Ala Asn Gly Gly Lieu. Glin Val Lys
35

4O

45

Ala Asn Ala Ser Ala Pro Pro Lys Ile Asin Gly Ser Ser Val Gly Lieu
SO

55

6O

Lys Ser Cys Ser Lieu Lys Thr Glin Glu Asp Thr Pro Ser Ala Pro Ala
65

70

7s

8O

Pro Arg Thr Phe Ile Asn Gln Lieu Pro Asp Trp Ser Met Lieu. Lieu Ala
85

90

95

Ala Ile Thir Thr Ala Phe Lieu Ala Ala Glu Lys Gln Trp Met Met Lieu
1OO

105

11 O

Asp Trp Llys Pro Lys Arg Pro Asp Met Lieu Val Asp Pro Phe Gly Lieu
115

12 O

125

Gly Ser Ile Val Gln His Gly Lieu Val Phe Arg Glin Asn Phe Ser Ile
13 O

135

14 O

Arg Ser Tyr Glu Ile Gly Ala Asp Arg Thr Ala Ser Ile Glu Thr Val
145

150

155

160

Met Asn His Lieu. Glin Glu Thir Ala Lieu. Asn His Val Llys Ser Ala Gly
1.65

17O

17s

Lieu Met Asn Asp Gly Phe Gly Arg Thr Pro Glu Met Tyr Lys Lys Asp
18O

185

19 O

Lieu. Ile Trp Val Val Ala Lys Met Glin Val Met Val Asn Arg Tyr Pro
195

2OO

2O5

Thir Trp Gly Asp Thr Val Glu Val Asn. Thir Trp Val Asp Llys Lieu. Gly
21 O

215

22O

Lys Asn Gly Met Arg Arg Asp Trp Lieu. Ile Ser Asp Cys Asn Thr Gly
225

23 O

235

24 O

Glu Ile Lieu. Thr Arg Ala Ser Ser Val Trp Val Met Met Asn Glin Lys
245

250

255

Thir Arg Arg Lieu. Ser Lys Ile Pro Asp Glu Val Arg Arg Glu Ile Glu
26 O

265

27 O

Pro His Phe Val Asp Ser Pro Pro Val Ile Glu Asp Asp Asp Arg Llys
27s

28O

285

Lieu Pro Llys Lieu. Asp Asp Llys Thr Ala Asp Ser Ile Arg Lys Gly Lieu.
29 O

295

3 OO

Thr Pro Llys Trp Asn Asp Lieu. Asp Val Asn Gln His Val Asn. Asn. Wall
3. OS

310

315

32O

Lys Tyr Ile Gly Trp Ile Lieu. Glu Ser Thr Pro Glin Glu Ile Leu Glu
3.25

330

335

Thr Glin Glu Lieu. Cys Ser Lieu. Thir Lieu. Glu Tyr Arg Arg Glu. Cys Gly
34 O

345

35. O

Arg Glu Ser Val Lieu. Glu Ser Lieu. Ser Ala Ala Asp Pro Ser Gly Lys
355

360

365

Gly Phe Gly Ser Glin Phe Gln His Lieu. Lieu. Arg Lieu. Glu Asp Gly Gly
37 O

375

38O
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Glu Ile Val Lys Gly Arg Thr Glu Trp Arg Pro Llys Thr Ala Gly Ile
385

390

395

4 OO

Asn Gly Ala Ile Pro Ser Gly Glu Thir Ser Pro Gly Asp Ser
4 OS

41O

What is claimed is:

1. A method of producing triacylglycerols (TAGs) com
prising medium-chain fatty acids (MCFAS) in an organism,
comprising:
introducing a transgene into the organism, wherein the
transgene comprises at least one nucleic acid sequence
encoding an acyltransferase, wherein the at least one
acyltransferase exhibits a Substrate specificity for Satu
rated fatty acids;
thereby producing TAGs comprising MCFAS in the organ
1S.

2. The method of claim 1, wherein at least 20% of the TAGs

comprising MCFAs have a C8:0 or a C10:0 at sn-2 position.
3. The method of claim 1, wherein the saturated fatty acids
are selected from the group consisting of C8:0 and C10:0.
4. The method of claim 1, wherein the at least one acyl
transferase is a lysophosphatidic acid acyltransferase (LPAT)
or a diacylglycerol acyltransferase (DGAT).
5. The method of claim 1, wherein the at least one acyl
transferase is a lysophosphatidic acid acyltransferase (LPAT)
and a diacylglycerol acyltransferase (DGAT).
6. The method of claim 4, wherein the nucleic acid

sequence encoding the LPAT is selected from the group con
sisting of a sequence having at least 95% sequence identity to
SEQID NO:1 and a sequence having at least 95% sequence
identity to SEQID NO:3.
7. The method of claim 4, wherein the nucleic acid

sequence encoding the DGAT is selected from the group
consisting of a sequence having at least 95% sequence iden
tity to SEQ ID NO:7 and a sequence having at least 95%
sequence identity to SEQID NO:9.
8. The method of claim 1, wherein the nucleic acid

sequence encoding the at least one acyltransferase is selected
from the group consisting of a nucleic acid sequence having at
least 95% sequence identity to SEQID NO:1, a nucleic acid
sequence having at least 95% sequence identity to SEQ ID
NO:3, a nucleic acid sequence having at least 95% sequence
identity to SEQID NO:7, and a nucleic acid sequence having
at least 95% sequence identity to SEQID NO:9.
9. The method of claim 1, wherein the organism further
comprises a nucleic acid sequence encoding a medium-chain
fatty acid (MCFA)-specific thioesterase FatB.
10. The method of claim 9, wherein the nucleic acid

sequence encoding the MCFA-specific thioesterase FatB is
selected from the group consisting of a nucleic acid sequence

having at least 95% sequence identity to SEQ ID NO:11, a
nucleic acid sequence having at least 95% sequence identity
to SEQID NO:13, and a nucleic acid sequence having at least
95% sequence identity to SEQID NO:15.
11. The method of claim 1, wherein the organism is
selected from the group consisting of a plant and a microbe.
12. The method of claim 11, wherein the plant is Camelina
Sativa.

13. The method of claim 1, wherein the transgene com
prises a promoter.
14. The method of claim 13, wherein the promoter is a
seed-specific promoter.
15. The method of claim 11, wherein the at least one

nucleic acid sequence encoding an acyltransferase is oper
ably linked to a seed-specific promoter.

16. The method of claim 15, wherein the medium-chain

fatty acids are produced in the seed.
17. The method of claim 1, wherein the introducing step is
performed using Agrobacterium transformation, particle
bombardment, or electroporation of protoplasts.
18. A method of producing triacylglycerols (TAGs) com
prising medium-chain fatty acids (MCFAS), comprising:
providing an organism comprising a transgene, wherein
the transgene comprises at least one nucleic acid
sequence encoding an acyltransferase, wherein the at
least one acyltransferase exhibits a Substrate specificity
for saturated fatty acids;
growing the organism under appropriate conditions; and
obtaining TAGs comprising MCGAS from the organism.
19. The method of claim 17, wherein the TAGs are used in

biofuel, jet fuel, detergents, and chemical feedstocks.
20. A method of increasing the amount of triacylglycerols
(TAGs) comprising medium-chain fatty acids (MCFAs) in the
seed oil of a plant, comprising:
providing a plant comprising a nucleic acid encoding a
FatB polypeptide;
introducing a heterologous nucleic acid molecule into the
plant comprising at least one nucleic acid sequence
encoding an acyltransferase, wherein the at least one
acyltransferase exhibits a Substrate specificity for Satu
rated fatty acids,
thereby increasing the amount of TAGs comprising
MCFAs in the seed oil of the plant without significantly
changing the total oil content in the seed.
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